Tabula Rasa HealthCare (TRHC) 10-Q 9 Nov 17 2017 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2017	Oct. 31, 2017
Document and Entity Information
Entity Registrant Name	Tabula Rasa HealthCare, Inc.
Entity Central Index Key	1,651,561
Document Type	10-Q
Document Period End Date	Sep. 30, 2017
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Entity Common Stock, Shares Outstanding		17,848,999
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	Q3

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Current assets:
Cash	$ 5,939	$ 4,345
Accounts receivable, net	16,631	6,646
Inventories	2,781	2,911
Rebates receivable	342	312
Prepaid expenses	2,278	869
Other current assets	315	581
Total current assets	28,286	15,664
Property and equipment, net	8,872	6,409
Software development costs, net	4,264	3,350
Goodwill	63,125	21,686
Intangible assets, net	63,347	25,297
Other assets	647	333
Total assets	168,541	72,739
Current liabilities:
Current portion of long-term debt	927	674
Acquisition-related consideration payable	50	568
Acquisition-related contingent consideration	15,224	1,493
Accounts payable	14,366	6,115
Accrued expenses and other liabilities	8,101	2,159
Total current liabilities	38,668	11,009
Line of credit	35,000
Long-term debt	1,019	1,072
Long-term acquisition-related contingent consideration	13,652	1,515
Deferred income tax liability	1,592	832
Other long-term liabilities	2,637	2,205
Total liabilities	92,568	16,633
Commitments and contingencies (Note 16)
Stockholders' equity (deficit):
Preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares issued and outstanding at September 30, 2017 and December 31, 2016
Common stock, $0.0001 par value; 100,000,000 shares authorized, 17,905,402 and 16,628,476 shares issued and 17,831,936 and 16,628,476 shares outstanding at September 30, 2017 and December 31, 2016, respectively	2	2
Additional paid-in capital	108,503	91,027
Treasury stock, at cost; 73,466 and no shares at September 30, 2017 and December 31, 2016, respectively	(959)
Accumulated deficit	(31,573)	(34,923)
Total stockholders' equity	75,973	56,106
Total liabilities and stockholders' equity	$ 168,541	$ 72,739

CONSOLIDATED BALANCE SHEETS (pa

CONSOLIDATED BALANCE SHEETS (parenthetical) - $ / shares	Sep. 30, 2017	Dec. 31, 2016
CONSOLIDATED BALANCE SHEETS
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	17,905,402	16,628,476
Common stock, shares outstanding	17,831,936	16,628,476
Treasury stock (in shares)	73,466	0

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Revenue:
Product revenue	$ 24,621	$ 20,731	$ 71,391	$ 58,732
Service revenue	8,647	3,443	19,222	8,017
Total revenue	33,268	24,174	90,613	66,749
Cost of revenue, exclusive of depreciation and amortization shown below:
Product cost	18,979	15,951	54,847	44,103
Service cost	4,486	1,232	9,241	3,135
Total cost of revenue	23,465	17,183	64,088	47,238
Gross profit	9,803	6,991	26,525	19,511
Operating expenses:
Research and development	1,527	1,028	4,037	2,878
Sales and marketing	1,325	881	3,869	2,511
General and administrative	4,098	2,053	16,097	5,762
Change in fair value of acquisition-related contingent consideration expense	923	47	960	146
Depreciation and amortization	2,166	1,276	5,730	3,415
Total operating expenses	10,039	5,285	30,693	14,712
Income (loss) from operations	(236)	1,706	(4,168)	4,799
Other (income) expense:
Change in fair value of warrant liability		(626)		(639)
Interest expense	174	1,242	327	4,250
Loss on extinguishment of debt		1,396		1,396
Total other expense	174	2,012	327	5,007
Income (loss) before income taxes	(410)	(306)	(4,495)	(208)
Income tax (benefit) expense	(8,105)	(164)	(7,845)	11
Net income (loss)	7,695	(142)	3,350	(219)
Net income (loss) attributable to common stockholders:
Basic	7,695	1,228	3,350	1,080
Diluted	$ 7,695	$ (803)	$ 3,350	$ (894)
Net income (loss) per share attributable to common stockholders:
Basic (in dollars per share)	$ 0.46	$ 0.25	$ 0.20	$ 0.22
Diluted (in dollars per share)	$ 0.41	$ (0.08)	$ 0.18	$ (0.09)
Weighted average common shares outstanding
Basic (in shares)	16,699,102	4,918,885	16,483,169	4,817,285
Diluted (in shares)	18,646,031	10,333,723	18,411,800	10,232,050

CONSOLIDATED STATEMENTS OF STOC

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - 9 months ended Sep. 30, 2017 - USD ($) $ in Thousands	Common Stock	Held in Treasury	Additional Paid-in Capital	Accumulated Deficit	Total
Balance at beginning of period at Dec. 31, 2016	$ 2		$ 91,027	$ (34,923)	$ 56,106
Balance at beginning of period (in shares) at Dec. 31, 2016	16,628,476
Increase (Decrease) in Stockholders' Equity
Issuance of common stock in connection with acquisition			11,541		11,541
Issuance of common stock in connection with acquisition (in shares)	520,821
Issuance of restricted stock (in shares)	35,596
Shares surrendered by stockholder	(246)
Shares repurchased		$ (959)			(959)
Shares repurchased (in shares)		(73,466)
Net exercise of stock warrants (in shares)	28,431
Net exercise of stock options			(2,035)		(2,035)
Net exercise of stock options (in shares)	593,887
Exercise of stock options			194		194
Exercise of stock options (in shares)	98,437
Stock based compensation expense			7,776		7,776
Net income				3,350	3,350
Balance at end of period at Sep. 30, 2017	$ 2	$ (959)	$ 108,503	$ (31,573)	$ 75,973
Balance at end of period (in shares) at Sep. 30, 2017	17,905,402	(73,466)

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Cash flows from operating activities:
Net income (loss)	$ 3,350	$ (219)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization	5,730	3,415
Amortization of deferred financing costs and debt discount	72	1,255
Payment of imputed interest on debt		(3,893)
Deferred taxes	(8,137)	(27)
Stock-based compensation	7,776	481
Change in fair value of warrant liability		(639)
Change in fair value of acquisition-related contingent consideration	960	146
Other noncash items	17
Loss on extinguishment of debt		1,396
Changes in operating assets and liabilities, net of effect from acquisition:
Accounts receivable, net	(1,676)	(1,729)
Inventories	130	(305)
Rebates receivable	(30)	759
Prepaid expenses and other current assets	(169)	(114)
Other assets	(58)	(171)
Accounts payable	29	(191)
Accrued expenses and other liabilities	3,274	340
Other long-term liabilities	432	1,973
Net cash provided by operating activities	11,700	2,477
Cash flows from investing activities:
Purchases of property and equipment	(2,618)	(2,947)
Software development costs	(2,223)	(1,201)
Purchase of intangible assets		(29)
Change in restricted cash		200
Purchase of businesses, net of cash acquired	(34,452)	(1,000)
Net cash used in investing activities	(39,293)	(4,977)
Cash flows from financing activities:
Payments for repurchase of common stock	(959)
Proceeds from exercise of stock options	194	0
Payments for employee taxes for shares withheld	(2,123)
Payments for debt financing costs	(220)	(1,521)
Borrowings on line of credit	35,342	6,000
Repayments of line of credit	(342)
Payments of acquisition-related consideration	(550)	(180)
Repayment of note payable related to acquisition		(14,337)
Payments of initial public offering costs	(132)	(2,191)
Payments of contingent consideration	(1,498)	(1,895)
Proceeds from long-term debt		30,000
Repayments of long-term debt	(525)	(13,609)
Net cash provided by financing activities	29,187	2,267
Net increase (decrease) in cash	1,594	(233)
Cash, beginning of period	4,345	2,026
Cash, end of period	5,939	1,793
Supplemental disclosure of cash flow information
Acquisition of equipment under capital leases	50	1,470
Additions to property, equipment, and software development purchases included in accounts payable	46	238
Deferred offering costs included in accounts payable		1,006
Cash paid for interest	156	7,901
Decretion of redeemable convertible preferred stock to redemption value		$ (2,439)
Stock issued in connection with acquisition	$ 11,541

Nature of Business

Nature of Business	9 Months Ended
	Sep. 30, 2017
Nature of Business
Nature of Business	1. Nature of Business Tabula Rasa HealthCare, Inc. (the “Company”) provides patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations, lower healthcare costs and manage risk. The Company delivers its solutions through a comprehensive suite of technology-enabled products and services for medication risk management and risk adjustment. The Company serves healthcare organizations that focus on populations with complex healthcare needs and extensive medication requirements. The Company's suite of cloud-based software solutions provides prescribers, pharmacists and healthcare organizations with sophisticated and innovative tools to better manage the medication-related needs of patients. On October 4, 2016, the Company closed its initial public offering (the “IPO”) in which the Company issued and sold 4,300,000 shares of common stock, plus the exercise of the underwriters’ option to purchase an additional 645,000 shares of common stock, at an issuance price of $12.00 per share. The Company received net proceeds of $55,186 after deducting underwriting discounts and commissions of $4,154 but before deducting other offering expenses. In addition, upon the closing of the IPO, all of the Company’s then outstanding Class A Non-Voting common stock and Class B Voting common stock, totaling 5,583,405 shares, were automatically redesignated into shares of common stock, and all of the Company’s then outstanding convertible preferred stock converted into an aggregate of 5,089,436 shares of common stock. In addition, 202,061 shares of common stock were issued upon the automatic net exercise of outstanding warrants to purchase common stock that would have otherwise terminated immediately prior to the closing of the IPO. Additionally, in connection with the closing of the IPO, outstanding warrants to purchase shares of preferred stock converted into warrants to purchase an aggregate of 463,589 shares of common stock.

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2017
Summary of Significant Accounting Policies
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies The Company's significant accounting policies are disclosed in the Company’s audited consolidated financial statements for the year ended December 31, 2016, which are included in the Company’s annual report filed on Form 10-K on March 14, 2017 . Since the date of those audited consolidated financial statements, there have been no changes to the Company's significant accounting policies, including the status of recent accounting pronouncements, other than those detailed below. (a) Basis of Presentation The accompanying unaudited consolidated financial statements of the Company have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) and applicable rules and regulations of the Securities and Exchange Commission (the “SEC”) regarding interim financial reporting. The unaudited interim consolidated financial statements have been prepared on the same basis as the annual audited consolidated financial statements and, in the opinion of management, reflect all adjustments ( consisting of normal recurring accruals and adjustments) , necessary for the fair statement of the Company's interim consolidated financial position for the periods indicated. The interim results for the three and nine months ended September 30, 2017 are not necessarily indicative of results to be expected for the year ending December 31, 2017, any other interim periods, or any future year or period. As such, the information included in this quarterly report on Form 10-Q should be read in conjunction with the consolidated financial statements and accompanying notes included in the Company’s annual report as filed on Form 10-K. (b) Liquidity The Company's unaudited consolidated financial statements have been prepared on the basis of continuity of operations, realization of assets and the satisfaction of liabilities in the ordinary course of business. Management believes that the Company's cash on hand of $5,939 as of September 30, 2017, cash flows from operations and borrowing availability under the Amended and Restated 2015 Revolving Line are sufficient to fund the Company's planned operations through at least December 31, 2018. See Note 10 for additional information. (c) Use of Estimates The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates or assumptions. (d) Revenue Recognition The Company recognizes revenue from product sales or services rendered when (i) persuasive evidence of an arrangement exists, (ii) services have been rendered, (iii) the price to its client is fixed or determinable and (iv) collectability is reasonably assured. When the Company enters into arrangements with multiple deliverables, it applies the accounting guidance for revenue arrangements with multiple deliverables and evaluates each deliverable to determine whether it represents a separate unit of accounting based on the following criteria: (i) whether the delivered item has value to the customer on a standalone basis, and (ii) if the contract includes a general right of return relative to the delivered item, delivery or performance of the undelivered item(s) is considered probable and substantially in the control of the Company. Revenue is allocated to each element in an arrangement based on a selling price hierarchy. The selling price for a deliverable is based on estimated selling prices ("ESP") as vendor specific objective evidence or third party evidence is not available. The Company establishes ESP for the elements of its arrangements based upon its pricing practices and class of customers. The stated prices for the various deliverables of the Company's contracts are consistent across classes of customers. Product Revenue The Company enters into multiple-element arrangements with healthcare organizations to provide software enabled medication risk management solutions. Under these contracts, revenue is generated through the components listed below. Prescription medication revenue The Company sells prescription medications directly to healthcare organizations through its prescription fulfillment pharmacies. Prescription medication fees are based upon the prices stated in customer contracts for the prescription and include a dispensing fee. Prescription medication revenue, including dispensing fees, is recognized when the product is shipped to the customer. Prescription medications are considered a separate unit of accounting. Per member per month fees — medication risk management services The Company receives a fixed monthly administrative fee for each member in the program contracted for medication risk management services. This fee, which is included in product revenue in the consolidated statement of operations, is recognized on a monthly basis as medication risk management services are provided. The services associated with the per member per month fees are considered a separate unit of accounting. Service Revenue The Company provides medication risk management services utilizing the Medication Risk Mitigation Matrix (“MRM Matrix”) technology alone, without the related fulfillment services, which are referred to as MRM Service Contracts. The Company began entering into these MRM Service Contracts in the third quarter of 2016. The Company’s MRM Service Contracts also include services provided by the SinfoníaRx business, which was acquired on September 6, 2017. The SinfoníaRx business provides Medication Therapy Management (“MTM”) technology and services for Medicare, Medicaid, and commercial health plans, which are referred to as MTM Contracts. See Note 4 for additional information about the acquisition of the SinfoníaRx business. The Company also enters into contracts with healthcare organizations to provide (i) risk adjustment and (ii) pharmacy cost management services, which include training client staff and providers about documentation and diagnosis coding, analyzing clients' data collection and submission processes, and delivering meaningful analytics for understanding reimbursement complexities. Under the MRM Service Contracts, MTM Contracts and risk adjustment contracts, there are generally three revenue generating components: Set up fees: The Company's contracts for Medication Risk Mitigation (“MRM”) and risk adjustment services often require customers to pay non-refundable set up fees, which are deferred and recognized over the estimated term of the contract. These fees are charged at the beginning of the customer relationship as compensation for the Company's efforts to prepare the customer and configure its system for the data collection process. The set up activities do not represent a separate unit of accounting as they do not have value apart from the broader MRM Service Contracts, MTM Contracts and risk adjustment contracts. Incremental direct costs associated with such set up activities are also deferred and amortized over the shorter of the estimated customer life or stated contract period. Per member per month fees The Company receives a fixed monthly fee for each member in the respective programs. These services represent a separate unit of accounting and are offered independently from any other services. Revenue for these services is recognized each month as the services are performed. Hourly consulting fees or transactional based fees The Company sometimes contracts with customers to perform various other services. Such services are billed on a time and materials basis, at agreed hourly rates, or on a per transaction basis. Consulting services represent a separate unit of accounting and are offered independently from any other services. Revenue for these services is recognized as time is incurred on the project. The Company's pharmacy cost management services include subscription revenue from customers and revenues from drug manufacturers for the sale of drug utilization data. Subscription revenue is recognized monthly as either a flat fee or as a percentage of monthly transactions incurred. Data and statistics fees from drug manufacturers are recognized as revenue when received due to the unpredictable nature of the payments and because fees are not fixed and determinable until received. (e) Cost of Product Revenue Cost of product revenue includes all costs directly related to the medication risk management offering, including costs relating to the Company's pharmacists' collaboration on a patient's medication management, clinical analysis of the results and, when necessary, offering guidance to the prescriber based upon the review of the medication risk mitigation matrix and the individual patient's medical history, as well as the fulfillment and distribution of prescription drugs. Costs consist primarily of the purchase price of the prescription drugs the Company dispenses, expenses to package, dispense and distribute prescription drugs, expenses associated with the Company's medication care plan support centers and prescription fulfillment centers, including employment costs and stock-based compensation, and expenses related to the hosting of the Company's technology platform. Such costs also include direct overhead expenses, as well as allocated miscellaneous overhead costs. The Company allocates miscellaneous overhead costs among functions based on employee headcount. (f) Cost of Service Revenue Cost of service revenue includes all labor costs, including stock-based compensation expense, directly related to the risk adjustment and pharmacy cost management services and expenses for claims processing, technology services and overhead costs. In addition, service costs include all costs directly related to servicing the Company’s MRM Service Contracts and MTM Contracts, which primarily consist of labor costs, consultant fees, technology services and overhead costs. (g) R ecent Accounting Pronouncements In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers ("ASU 2014-09") and has subsequently issued a number of amendments to ASU 2014-09. ASU 2014-09, as amended, represents a comprehensive new revenue recognition model that requires a company to recognize revenue to depict the transfer of promised goods or services to clients in an amount that reflects the consideration to which the Company expects to be entitled to receive in exchange for those goods or services. ASU 2014-09 sets forth a new five-step revenue recognition model which replaces the prior revenue recognition guidance in its entirety and is intended to eliminate numerous industry-specific pieces of revenue recognition guidance that have historically existed. For public companies, ASU 2014-09 is effective for annual reporting periods beginning after December 15, 2017 and interim reporting periods within that reporting period. Early adoption is permitted for annual reporting periods beginning after December 15, 2016; however, the Company does not intend to early adopt the new standard. Companies may use either a full retrospective or a modified retrospective approach to adopt ASU 2014-09. The Company intends to adopt the new standard effective January 1, 2018 but has not yet determined which transition method will be used. The Company is currently analyzing significant contracts with customers to determine the impact of the adoption of ASU 2014-09 on the Company’s consolidated financial statements and disclosures. The Company will continue to assess all potential impacts of the standard on existing and new customer contracts during 2017 and on the Company’s processes and internal controls over financial reporting. A final evaluation of the impact of the adoption of the new standard is expected to be completed by the end of 2017 . In July 2015, the FASB issued ASU 2015-11, Inventory (Topic 330): Simplifying the Measurement of Inventory ("ASU 2015-11"), which simplifies the subsequent measurement of inventories by replacing the current lower of cost or market test with a lower of cost and net realizable value test. ASU 2015-11 is effective for public business entities for fiscal years beginning after December 15, 2016, and interim periods within those fiscal years. Early adoption is permitted. The Company has adopted ASU 2015-11 effective January 1, 2017. The adoption of this standard did not have any impact on the Company's consolidated financial statements. In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) ("ASU 2016-02"). The new standard establishes a right-of-use ("ROU") model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. ASU 2016-02 is effective for annual periods beginning after December 15, 2018, including interim periods within those annual periods, with early adoption permitted. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. The Company is currently evaluating the potential impact of the adoption of this standard and anticipates that this standard will have a material impact on the Company’s consolidated financial statements, as all long-term leases will be capitalized on the consolidated balance sheet. In March 2016, the FASB issued ASU 2016-09, Compensation — Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting ("ASU 2016-09"). The amendments in this update simplify certain aspects related to how share-based payments are accounted for and presented in the financial statements. The new guidance requires excess tax benefits and tax deficiencies be recorded as an income tax benefit or expense in the statement of operations when the awards vest or are settled and as operating cash flows when realized. The excess tax benefits are recognized regardless of whether the benefit reduces income taxes payable in the current period. It also allows an employer to repurchase more of an employee's shares than it can today for tax withholding purposes without triggering liability accounting and to make a policy election to account for forfeitures as they occur. ASU 2016-09 is effective for fiscal years beginning after December 15, 2016, and interim periods within those fiscal years. The Company adopted ASU 2016-09 effective January 1, 2017. The Company elected to record forfeitures as they occur. There was no impact of this election because prior to the adoption the Company’s historical forfeitures were de minimus. The adoption of this new standard resulted in the recognition of a tax benefit in the amount of $2,830 in the consolidated statement of operations related to tax windfall benefits generated during the nine months ended September 30, 2017. In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments ("ASU 2016-15"). ASU 2016-15 provides new guidance to reduce diversity in practice in how certain transactions are classified in the statement of cash flows. ASU 2016-15 is effective for financial statements issued for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. The Company is currently evaluating the potential impact of the adoption of ASU 2016-15 on the Company's consolidated financial statements. In January 2017, the FASB issued Accounting Standards Update No. 2017-01, Business Combinations (“ASU 2017-01”). ASU 2017-01 provides guidance for evaluating whether a set of transferred assets and activities (the “set”) should be accounted for as an acquisition of a business or group of assets. The guidance provides a screen to determine when a set does not qualify to be a business. When substantially all of the fair value of the gross assets acquired (or disposed of) is concentrated in an identifiable asset or a group of similar assets, the set is not a business. Also to be considered a business, the set would have to include an input and a substantive process that together significantly contribute to the ability to create outputs. ASU 2017-01 is effective for financial statements issued for fiscal years beginning after December 15, 2017. The Company is currently evaluating the potential impact of the adoption of ASU 2017-01 on the Company's consolidated financial statements. In January 2017, the FASB issued ASU No. 2017-04, Intangibles – Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment ("ASU 2017-04"). ASU 2017-04 simplifies the accounting for goodwill impairment by eliminating the requirement to calculate the implied fair value of goodwill to measure an impairment charge. Instead, entities will be required to record an impairment charge based on the excess of a reporting unit’s carrying value over its fair value. ASU 2017-04 is effective for financial statements issued for fiscal years beginning after December 15, 2019. The Company is currently evaluating the potential impact of the adoption of ASU 2017-04 on the Company's consolidated financial statements. In May 2017, the FASB issued ASU No. 2017-09, Compensation – Stock Compensation (Topic 718): Scope of Modification Accounting (“ASU 2017-09”). ASU 2017-09 amends the scope of modification accounting for share-based payment arrangements. The guidance requires modification accounting only if the fair value, vesting conditions, or the classification of the award (as equity or liability) changes as a result of a change in terms or conditions. ASU 2017-09 is effective for financial statements issued for fiscal years beginning after December 15, 2017. The Company is currently evaluating the potential impact of the adoption of ASU 2017-09 on the Company's consolidated financial statements.

Net Income (Loss) per Share

Net Income (Loss) per Share	9 Months Ended
	Sep. 30, 2017
Net Income (Loss) per Share
Net Income (Loss) per Share	3. Net Income (Loss) per Share Basic net income (loss) per share is computed by dividing net income (loss) attributable to common stockholders by the weighted average number of shares of common stock of the Company outstanding during the period. The Company computed net income (loss) per share of common stock using the treasury stock method for the three and nine months ended September 30, 2017, and using the two-class method required for participating securities for the three and nine months ended September 30, 2016. The Company considered its redeemable convertible preferred stock to be participating securities as the holders of the preferred stock were entitled to receive a dividend in the event that a dividend was paid on common stock. Diluted net income (loss) per share is computed by dividing net income (loss) attributable to common stockholders by the weighted average number of shares of common stock during the period plus the impact of dilutive securities, to the extent that they are not anti-dilutive. The following table presents the calculation of basic and diluted net income (loss) per share for the Company’s common stock : Three Months Ended Nine Months Ended September 30, September 30, 2017 2016 2017 2016 Numerator: Net income (loss) $ 7,695 $ (142) $ 3,350 $ (219) Decretion of redeemable convertible preferred stock — 2,641 — 2,439 Undistributed income attributable to redeemable convertible preferred stockholders — (1,271) — (1,140) Net income (loss) attributable to common stockholders, basic $ 7,695 $ 1,228 $ 3,350 $ 1,080 Decretion of redeemable convertible preferred stock — (2,641) — (2,439) Revaluation of warrant liability, net of tax — (661) — (675) Adjustment to undistributed income attributable to redeemable convertible preferred stockholders — 1,271 — 1,140 Net income (loss) attributable to common stockholders, diluted $ 7,695 $ (803) $ 3,350 $ (894) Denominator (basic): Weighted average shares of common stock outstanding, basic 16,699,102 4,918,885 16,483,169 4,817,285 Denominator (diluted): Weighted average shares of common stock outstanding 16,699,102 4,918,885 16,483,169 4,817,285 Effect of potential dilutive securities: Weighted average dilutive effect of stock options 1,235,883 — 1,308,202 — Weighted average dilutive effect of restricted shares 711,046 607,988 — Weighted average dilutive effect of common shares from warrants — — 12,441 — Dilutive effect from preferred stock and preferred stock warrants assuming conversion — 5,414,838 — 5,414,765 Weighted average shares of common stock outstanding, diluted 18,646,031 10,333,723 18,411,800 10,232,050 Net income per share attributable to common stockholders, basic $ 0.46 $ 0.25 $ 0.20 $ 0.22 Net income (loss) per share attributable to common stockholders, diluted $ 0.41 $ (0.08) $ 0.18 $ (0.09) The following potential common shares, presented based on amounts outstanding at each period end, were excluded from the calculation of diluted net income (loss) per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect: Three Months Ended Nine Months Ended September 30, September 30, 2017 2016 2017 2016 Stock options to purchase common stock — 2,723,193 — 2,723,193 Restricted stock — 722,646 — 722,646 Common stock warrants — 213,806 — 213,806 — 3,659,645 — 3,659,645 On October 4, 2016, the Company closed its IPO in which the Company issued and sold 4,300,000 shares of common stock, plus the exercise of the underwriters’ option to purchase an additional 645,000 shares, at an issuance price of $12.00 per share. See Notes 1 and 13 for additional information.

Acquisitions

Acquisitions	9 Months Ended
	Sep. 30, 2017
Acquisition
Acquisition	4. Acquisitions Sinfon í aRx On September 6, 2017, the Company, TRCRD, Inc., a Delaware corporation and wholly-owned subsidiary of the Company (“Merger Sub I”), and TRSHC Holdings, LLC, a Delaware limited liability company and a wholly-owned subsidiary of the Company (“Merger Sub II,” and together with Merger Sub I, the “Merger Subs”), entered into, and consummated the transactions contemplated by, an Agreement and Plan of Merger (the “Merger Agreement”), by and among the Company, the Merger Subs, Sinfonía HealthCare Corporation, a Delaware corporation (“Sinfonía”), Michael Deitch, Fletcher McCusker and Mr. Deitch in his capacity as the Stockholders’ Representative. Under the terms of the Merger Agreement, the Company acquired the SinfoníaRx business (“SRx”) as a result of Merger Sub I merging with and into Sinfonía, with Sinfonía surviving as a wholly-owned subsidiary of the Company (the “First Merger”), and, immediately following the First Merger, Sinfonía merging with and into Merger Sub II, with Merger Sub II surviving as a wholly-owned subsidiary of the Company. The SRx business provides MTM technology and services for Medicare, Medicaid, and commercial health plans. The consideration for the acquisition of SRx was comprised of (i) cash consideration of $35,000 paid upon closing, subject to certain customary post-closing adjustments, in each case upon the terms and subject to the conditions contained in the Merger Agreement; (ii) common stock consideration issued upon closing valued at $11,541; and (iii) contingent purchase price consideration with a preliminary estimated fair value of $26,406 to be paid 50% in cash and 50% in the Company’s common stock, subject to adjustments as set forth in the Merger Agreement, based on the achievement of certain performance goals for each of the twelve-month periods ended December 31, 2017 and December 31, 2018. In addition, the Company is not obligated to pay more than $35,000 in cash and the Company’s common stock for the first contingent payment, or more than $130,000 for the aggregate overall closing consideration (not taking into account certain adjustments set forth in the Merger Agreement) and contingent payments. A portion of the cash merger consideration is being held in escrow to secure potential claims by the Company for indemnification under the Merger Agreement and in respect of adjustments to the acquisition consideration. The Company issued 520,821 shares of the Company’s common stock valued at $19.20 per share in satisfaction of the stock consideration issued at closing. The value for the stock consideration issued was calculated based on the arithmetic average of the daily volume-weighted average trading price per share of the Company’s common stock for the 20 trading days ended on and including the trading day prior to the date of the Merger Agreement, using trading prices reported on the NASDAQ Global Market. The stock consideration issued at the closing of the acquisition had an acquisition-date fair value of $11,541. In connection with the acquisition of SRx, the Company incurred direct acquisition costs of $949, which are recorded in general and administrative expenses in the consolidated statements of operations. The Company, with the assistance of a third-party appraiser, utilized a Monte Carlo simulation to determine the estimated acquisition-date fair value of the acquisition-related contingent consideration of $26,406. The fair value measurement was based on significant inputs not observable in the market and thus represents a Level 3 measurement within the fair value hierarchy. The following table summarizes the purchase price consideration based on the estimated acquisition-date fair value of the acquisition consideration: Cash consideration at closing, net of post-closing adjustments $ Stock consideration at closing 11,541 Estimated fair value of contingent consideration 26,406 Total fair value of acquisition consideration $ 72,617 The following table summarizes the preliminary allocation of the purchase price based on the estimated fair values of the assets acquired and liabilities assumed at the date of acquisition: Cash $ 218 Accounts receivable 8,309 Prepaid expenses and other current assets 1,001 Property and equipment 1,419 Other assets 94 Trade name 4,429 Developed technology 12,640 Client relationships 19,579 Non-competition agreement 4,497 Goodwill 41,439 Total assets acquired $ 93,625 Accrued expenses and other liabilities (2,667) Trade accounts payable (8,769) Debt assumed (675) Deferred income tax liability (8,897) Total purchase price, including contingent consideration of $26,406 $ 72,617 The purchase price was allocated to the tangible assets and identifiable intangible assets acquired and liabilities assumed based on their acquisition-date estimated fair values. The identifiable intangible assets principally included a trade name, developed technology, client relationships, and a non-competition agreement, each of which are subject to amortization on a straight-line basis being amortized over a weighted average of 10, 8, 7.56 and 5 years, respectively. The weighted average amortization period for acquired intangible assets as of the date of acquisition is 7.68 years. The Company, with the assistance of a third-party appraiser, assessed the fair value of the assets of SRx. The fair values of the trademarks and technology were estimated using the relief from royalty method. The Company, with the assistance of a third party appraiser, derived the hypothetical royalty income from the projected revenues of SRx. The fair value of client relationships was estimated using a multi period excess earnings method. To calculate fair value, the Company, with the assistance of a third party appraiser, used cash flows discounted at a rate considered appropriate given the inherent risks associated with each client grouping. The fair value of the non-competition agreement was estimated using the differential approach which involves valuing the business under two different scenarios. The first valuation assumes the non-compete agreement is in place and the second valuation assumes that it is not. The difference in the value of the business under each approach is attributed to the non-compete agreement. The useful lives of the intangible assets were estimated based on the expected future economic benefit of the assets and is being amortized over the estimated useful life in proportion to the economic benefits consumed using the straight-line method. The amortization of intangible assets is not deductible for income tax purposes. The Company believes the goodwill related to the acquisition was a result of providing the Company exposure to a larger customer base that will enable the Company to leverage its technology in the broader market, as well as offering cross-selling market exposure opportunities. The goodwill is not deductible for income tax purposes. Revenue from SRx is recorded primarily based on a fixed monthly fee for each eligible member, or per member per month, in the respective programs. Revenue from SRx is also comprised of transactional fees based on a fixed fee per comprehensive medication review. Revenue for these services and the related costs are recognized each month as the services are performed and costs are incurred, and are included in service revenue and cost of revenue – service cost, respectively, in the consolidated statements of operations. For the three and nine months ended September 30, 2017, service revenue of $2,638 and net income of $285 from SRx were included in the Company’s consolidated statements of operations since the acquisition date. The fair value of the assets and liabilities related to the acquisition of SRx are based on a preliminary valuation report. The Company continues to evaluate the fair value of certain assets and liabilities related to the acquisition, including the measurement technique used to value the contingent consideration. Additional information, which existed as of the acquisition date but was at that time unknown to the Company, may become known during the remainder of the measurement period. Changes to amounts recorded as a result of the final valuation may result in a corresponding adjustment to these assets and liabilities, including goodwill. The determination of the estimated fair values of all assets acquired is expected to be completed within one year from the date of acquisition. IntermedRx On September 15, 2016, the Company acquired certain assets, consisting primarily of intellectual property and software assets of 9176-1916 Quebec Inc. (an entity indirectly controlled by our Chief Scientific Officer, Jacques Turgeon). The intellectual property and software assets were previously licensed by us and are integrated into the Company’s Medication Risk Mitigation Matrix. The purchase price consisted of cash consideration of $6,000, consisting of $1,000 which was paid upon closing, $4,400 paid during the fourth quarter of 2016, $550 paid on September 15, 2017, and $50 paid during the fourth quarter of 2017. In addition to the cash consideration, the purchase price included an aggregate of $5,000 worth of common stock, which amounted to the issuance of 395,407 shares of common stock during the fourth quarter of 2016. The deferred acquisition cash consideration of $5,000 was recorded at its acquisition-date fair value of $4,955, using an assumed cost of debt of 7.8%. The $45 discount was amortized to interest expense using the effective interest method through the consideration payment date. The Company amortized $10 and $2 of the discount to interest expense for the three months ended September 30, 2017 and 2016, respectively. The Company amortized $32 and $2 of the discount to interest expense for the nine months ended September 30, 2017 and 2016, respectively. These amounts are included in acquisition-related consideration payable in the consolidated balance sheets as of September 30, 2017. As of September 30, 2017, the acquisition-related consideration payable balance was $50. Proforma The unaudited pro forma results presented below include the results of the SRx acquisition and the 9176-1916 Quebec Inc. acquisition as if they had been consummated as of January 1, 2016. The unaudited pro forma results include the amortization associated with acquired intangible assets, interest expense on the debt incurred to fund these acquisitions, insurance expense for additional required business insurance coverage, stock compensation expense related to options granted to the employees of SRx at the closing of the acquisition, and the estimated tax effect of adjustments to income before income taxes. Material nonrecurring charges directly attributable to the transactions are excluded, and consisted of direct acquisition costs of $855 and $949 for the three and nine months ended September 30, 2017, respectively. In addition, the unaudited pro forma results do not include any expected benefits of the acquisitions. Accordingly, the unaudited pro forma results are not necessarily indicative of either future results of operations or results that might have been achieved had the acquisitions been consummated as of January 1, 2016. Three Months Ended Three Months Ended Nine Months Ended Nine Months Ended September 30, September 30, September 30, September 30, 2017 2016 2017 2016 Revenue $ 39,420 $ 31,266 $ 112,079 $ 85,336 Net loss (727) (1,332) (5,098) (4,259) Net income (loss) per share attributable to common stockholders, basic (0.04) 0.12 (0.30) (0.32) Net loss per share attributable to common stockholders, diluted (0.04) (0.17) (0.30) (0.44)

Property and Equipment

Property and Equipment	9 Months Ended
	Sep. 30, 2017
Property, Plant and Equipment [Abstract]
Property and Equipment	5. Property and Equipment Depreciation and amortization expense on property and equipment for the three months ended September 30, 2017 and 2016 was $542 and $359, respectively. Depreciation and amortization expense on property and equipment for the nine months ended September 30, 2017 and 2016 was $1,396 and $889, respectively.

Software Development Costs

Software Development Costs	9 Months Ended
	Sep. 30, 2017
Software Development Costs
Software Development Costs	6. Software Development Costs The Company capitalizes certain costs incurred in connection with obtaining or developing internal-use software, including external direct costs of material and services and payroll costs for employees directly involved with the software development. As of September 30, 2017 and December 31, 2016, capitalized software costs consisted of the following: September 30, 2017 December 31, 2016 Software development costs $ 8,652 $ 6,501 Less: accumulated amortization (4,388) (3,151) Software development costs, net $ 4,264 $ 3,350 Capitalized software costs not yet subject to amortization $ 2,421 $ 911 Amortization expense for the three months ended September 30, 2017 and 2016 was $426 and $302, respectively. Amortization expense for the nine months ended September 30, 2017 and 2016 was $1,237 and $757, respectively.

Goodwill and Intangible Assets

Goodwill and Intangible Assets	9 Months Ended
	Sep. 30, 2017
Goodwill and Intangible Assets
Goodwill and Intangible Assets	7. Goodwill and Intangible Assets The Company’s goodwill and related changes during the nine months ended September 30, 2017 are as follows: Balance at January 1, 2017 $ 21,686 Goodwill from 2017 acquisition 41,439 Balance at September 30, 2017 $ 63,125 Goodwill is not amortized, but instead tested for impairment annually. The Company conducted its annual impairment test as of October 1, 2016 and determined that there were no indicators of impairment during 2016. The next annual impairment test will be conducted as of October 1, 2017, unless the Company identifies a triggering event in the interim. Management has not identified any triggering events during the nine months ended September 30, 2017. Intangible assets consisted of the following as of September 30, 2017 and December 31, 2016: Weighted Average Amortization Period Accumulated Intangible (in years) Gross Value Amortization Assets, net September 30, 2017 Trade names 8.48 $ 6,369 $ (1,102) $ 5,267 Client relationships 8.56 34,263 (4,528) Non-competition agreements 4.95 5,149 (465) 4,684 Developed technology 7.87 26,140 (2,504) Domain name 10.00 29 (4) 25 Total intangible assets $ 71,950 $ (8,603) $ Weighted Average Amortization Period Accumulated Intangible (in years) Gross Value Amortization Assets, net December 31, 2016 Trade names 5.00 $ 1,940 $ (791) $ 1,149 Client relationships 10.02 14,684 (3,289) 11,395 Non-competition agreements 4.64 652 (326) 326 Developed technology 7.76 13,500 (1,101) 12,399 Domain name 10.00 29 (1) 28 Total intangible assets $ 30,805 $ (5,508) $ 25,297 Amortization expense for intangible assets for the three months ended September 30, 2017 and 2016 was $1,198 and $614, respectively. Amortization expense for intangible assets for the nine months ended September 30, 2017 and 2016 was $3,095 and $1,767, respectively. The estimated amortization expense for each of the next five years and thereafter is as follows: Years Ending December 31, 2017 (October 1 - December 31) $ 2,398 2018 9,557 2019 9,115 2020 8,776 2021 8,763 Thereafter 24,738 Total estimated amortization expense $ 63,347

Accrued Expenses and Other Liab

Accrued Expenses and Other Liabilities	9 Months Ended
	Sep. 30, 2017
Accrued Liabilities and Other Liabilities
Accrued Expenses and Other Liabilities	8. Accrued Expenses and Other Liabilities At September 30, 2017 and December 31, 2016, accrued expenses and other liabilities consisted of the following: September 30, 2017 December 31, 2016 Employee related expenses $ 4,634 $ 1,174 Deferred revenue 1,526 851 Contract labor 733 — Interest 115 16 Deferred rent 150 13 Professional fees 169 — Income taxes payable 281 27 Other expenses 493 78 Total accrued expenses and other liabilities $ 8,101 $ 2,159

Notes Payable Related to Acquis

Notes Payable Related to Acquisition	9 Months Ended
	Sep. 30, 2017
Notes Payable Related to Acquisition
Notes Payable Related to Acquisition	9. Notes Payable Related to Acquisition In December 2014, the Company acquired all of the authorized, issued and outstanding equity interests of Medliance LLC ("Medliance"), which provides pharmacy cost management services through data analytics. As part of the acquisition-related consideration of the Medliance acquisition, the Company issued multiple subordinated convertible promissory notes (the "Medliance Notes") to the owners of Medliance for aggregate borrowings of $16,385. Interest was 8% and compounded annually. On July 1, 2016, the Company repaid the Medliance Notes with the proceeds from a long-term credit facility. Interest expense was $706 for the nine months ended September 30, 2016. No interest expense was recorded for the three months ended September 30, 2016. The Company recorded the Medliance Notes at their aggregate acquisition date fair values of $14,347 and the notes were accreted up to their face values of $16,385 over the 18 month term using the effective-interest method. For the nine months ended September 30, 2016, the Company amortized $755 of the discount to interest expense. No expense was recorded for the three months ended September 30, 2016.

Lines of Credit and Long-Term D

Lines of Credit and Long-Term Debt	9 Months Ended
	Sep. 30, 2017
Lines of Credit and Long-Term Debt
Lines of Credit and Long-Term Debt	10. Lines of Credit and Long-Term Debt (a) Lines of Credit On July 1, 2016, the Company entered into a Loan and Security Modification Agreement (the "Amended 2015 Revolving Line") with Western Alliance Bank, successor in interest to Bridge Bank, National Association (“Bridge Bank”), whereby the Company’s revolving line of credit, entered into with Bridge Bank in 2015, was amended to increase the Company's borrowing availability to up to $25,000 and extend the maturity date to July 1, 2018. The Company's ability to borrow under the Amended 2015 Revolving Line was based upon a specified borrowing base equal to the Company's trailing four months of monthly recurring revenue, as defined, from eligible recurring revenue contracts, as defined, through March 31, 2017 and based upon the Company's trailing three months of monthly recurring revenue, as defined, from eligible recurring revenue contracts, as defined, thereafter. Interest on the Amended 2015 Revolving Line was also amended to be calculated at a variable rate based upon Western Alliance Bank's prime rate plus 0.5%, with Western Alliance Bank's prime rate having a floor of 3.5%. Financial covenants under the Amended 2015 Revolving Line required that the Company (i) maintain an unrestricted cash and unused availability balance under the Amended 2015 Revolving Line of at least $3,000 at all times (the liquidity covenant), (ii) maintain a minimum EBITDA, as defined, of $2,500 for the quarter ending December 31, 2016 and thereafter, and (iii) maintain a minimum monthly recurring revenue retention rate of at least 90%, measured quarterly. On September 6, 2017, in connection with the acquisition of SRx, the Company entered into an Amended and Restated Loan and Security Agreement (the “Amended and Restated 2015 Revolving Line”) whereby the Amended 2015 Revolving Line was amended to extend the maturity date to September 6, 2020, and increase the Company's borrowing availability to up to $40,000 with a $1,000 sublimit for cash management services and letters of credit and foreign exchange transactions. The Company may also request an increase in the Amended and Restated 2015 Revolving Line of up to $10,000 upon the successful syndication of such additional amounts. Interest on the Amended and Restated 2015 Revolving Line was also amended to be calculated at a variable rate based upon Western Alliance Bank's prime rate plus an applicable margin which will range from (0.25%) to 0.25% depending on the Company’s leverage ratio, with Western Alliance Bank's prime rate having a floor of 3.5%. Financial covenants under the Amended and Restated 2015 Revolving Line require that the Company (i) maintain an unrestricted cash and unused availability balance under the Amended and Restated 2015 Revolving Line of at least $3,000 at all times (the liquidity covenant), (ii) maintain a leverage ratio of less than 2.50:1.00, on a trailing twelve-month basis starting with the twelve-month period ending December 31, 2017, measured quarterly, and (iii) maintain a minimum quarterly EBITDA starting with the quarter ending December 31, 2017 and each quarter thereafter, of at least 75% of the plan approved by the Company’s Board of Directors (the “Board”). In addition, the Company may not contract to make capital expenditures, excluding capitalized software development costs and tenant leasehold improvements, greater than $5,000 in any fiscal year without the consent of Western Alliance Bank. As of September 30, 2017, the Company was in compliance with all of the financial covenants related to the Amended and Restated 2015 Revolving Line, and management expects that the Company will be able to maintain compliance with the financial covenants. In September 2015, the Company arranged for Bridge Bank to issue a $500 letter of credit on its behalf in connection with the Company’s lease agreement for the office space in Moorestown, NJ. The letter of credit was issued under the Amended and Restated 2015 Revolving Line. The letter of credit renews annually and expires in September 2027 and reduces amounts available on the line of credit. See Note 16 for additional information. As of September 30, 2017, there was $35,000 outstanding under the Amended and Restated 2015 Revolving Line, and amounts available for borrowings under the Amended and Restated 2015 Revolving Line was $4,500. As of September 30, 2017, the interest rate on the Amended and Restated 2015 Revolving Line was 4.31% and interest expense was $100 for the three and nine months ended September 30, 2017. As of September 30, 2016, the interest rate on the Amended and Restated 2015 Revolving Line was 4.56% and interest expense was $169 and $449 for the three and nine months ended September 30, 2016, respectively. In connection with the Amended and Restated 2015 Revolving Line ( and all predecessor agreements prior to the amendment or the amendment and restatement thereof), the Company recorded deferred financing costs of $413. The Company is amortizing the deferred financing costs to interest expense using the effective-interest method over the term of the Amended and Restated 2015 Revolving Line and amortized $16 and $9 to interest expense for the three months ended September 30, 2017 and 2016, respectively, and $40 and $36 to interest expense for the nine months ended September 30, 2017 and 2016, respectively. (b) Capital Lease Obligations The following table represents the total capital lease obligations of the Company at September 30, 2017 and December 31, 2016: September 30, 2017 December 31, 2016 Capital leases $ 1,946 $ 1,746 Less current portion, net (927) (674) Total capital leases, less current portion, net $ 1,019 $ 1,072 The Company has entered into leases for certain equipment and software, which are recorded as capital lease obligations. These leases have annual interest rates ranging from 6% to 19%. Interest expense related to the capital leases was $49 and $56 for the three months ended September 30, 2017 and 2016, respectively. Interest expense related to the capital leases was $158 and $148 for the nine months ended September 30, 2017 and 2016, respectively. Amortization of assets held under capital leases is included in depreciation and amortization expense. The net book value of equipment and software acquired under capital lease was $2,213 and $2,364 as of September 30, 2017 and December 31, 2016, respectively, and are reflected in property and equipment on the consolidated balance sheets. (c) Long-Term Debt Maturities As of September 30, 2017, the Company's long-term debt consisted of capital lease obligations and is payable as follows: Total long-term debt Remainder of 2017 $ 293 2018 1,065 2019 725 2020 116 2021 5 2,204 Less amount representing interest (258) Present value of payments 1,946 Less current portion (927) Total long-term debt, net of current portion $ 1,019 (d) Other Financing In May 2016, the Company signed a prime vendor agreement with AmerisourceBergen Drug Corporation, which was effective March 2016 and requires a monthly minimum purchase obligation of approximately $1,750. The Company fully expects to meet this requirement. This agreement was subsequently amended and restated effective May 1, 2016 with a three-year term expiring April 2019. As of September 30, 2017 and December 31, 2016, the Company had $3,839 and $3,327, respectively, due to AmerisourceBergen Drug Corporation as a result of prescription drug purchases. Pursuant to the terms of a security agreement entered into in connection with the prime vendor agreement, AmerisourceBergen also holds a subordinated security interest in all of the Company’s assets.

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2017
Income Taxes
Income Taxes	11. Income Taxes For the nine months ended September 30, 2017, the Company recorded an income tax benefit of $7,845 . During the third quarter of 2017, in conjunction with the acquisition of SRx, the Company recognized a net deferred tax liability of $8,897 primarily related to intangible assets other than goodwill. The Company determined that the deferred tax liabilities related to the acquisition provide sufficient sources of recoverability to realize the Company’s deferred tax assets associated with those jurisdictions that file consolidated returns. As a result, the Company released $6,590 of its deferred tax asset valuation allowance and recognized an additional benefit of $2,830 related to tax windfall benefits generated in the nine months ended September 30, 2017. These tax benefits were partially offset by tax expense of $1,463 recorded based on the estimated annual effective tax rate expected for the full year. For the nine months ended September 30, 2016, the Company recognized tax expense of $11, which resulted in an effective tax rate of (5.3)%. For the nine months ended September 30, 2016, the Company recorded the tax provision based on the estimated annual effective tax rate expected for the full year which included current Federal alternative minimum tax, current state taxes and deferred tax expense associated with indefinite-lived deferred tax liabilities for goodwill amortization, in addition to a change in the valuation allowance related to deferred tax assets for income generated in the current period.

Other Long-term Liabilities

Other Long-term Liabilities	9 Months Ended
	Sep. 30, 2017
Other Long-term Liabilities
Other Long-term Liabilities	12. Other Long-term Liabilities Other long term liabilities as of September 30, 2017 and December 31, 2016 consisted of $2,637 and $2,205, respectively, which represents the long-term portion of deferred rent primarily related to the Company's operating leases for office space in Moorestown, NJ and a new space in South Carolina dedicated to software development, which the Company began to occupy in June 2017.

Stockholders' Equity

Stockholders' Equity	9 Months Ended
	Sep. 30, 2017
Stockholders' Equity
Stockholders' Equity	13. Stockholders' Equity (a) Capitalization and Initial Public Offering On October 4, 2016, the Company closed its IPO in which the Company issued and sold 4,300,000 shares of common stock, plus the exercise of the underwriters’ option to purchase an additional 645,000 shares of common stock, at an issuance price of $12.00 per share. The Company received net proceeds of $55,186 after deducting underwriting discounts and commissions of $4,154 but before deducting other offering expenses. In addition, upon the closing of the IPO, all of the Company’s then outstanding Class A Non-Voting common stock and Class B Voting common stock, totaling 5,583,405 shares, were automatically redesignated into shares of common stock, and all of the Company’s then outstanding convertible preferred stock converted into an aggregate of 5,089,436 shares of common stock. Upon completion of the IPO on October 4, 2016, the Company filed an amended and restated certificate of incorporation to, among other things, state that the aggregate number of shares of stock that the Company is authorized to issue is 100,000,000 shares of common stock, par value $.0001 per share, and 10,000,000 shares of undesignated preferred stock, par value $.0001 per share. (b) Common Stock Warrants During the nine months ended September 30, 2017, 28,431 shares of common stock were issued upon the net exercise of 32,216 warrants to purchase common stock at an exercise price of $1.55 per share. As of September 30, 2017, no warrants to purchase shares of common stock were outstanding. During the nine months ended September 30, 2016, the Company issued 210,817 shares of common stock upon the net exercise of warrants to purchase 232,787 shares of common stock. (c) Common Stock Repurchase On April 25, 2017 the Board authorized the Company to repurchase up to $5,000 of its common stock at prevailing market prices, from time to time, through open market, block and privately-negotiated transactions, at such times and in such amounts as management deems appropriate. The Company funds repurchases of its common stock through a combination of cash on hand, cash generated by operations or borrowings under the Amended and Restated 2015 Revolving Line. During the nine months ended September 30, 2017, the Company repurchased 73,466 shares at an average price of $13.05 per share for a total of $959. As of September 30, 2017, $4,041 of common stock remained available for repurchase.

Stock-Based Compensation

Stock-Based Compensation	9 Months Ended
	Sep. 30, 2017
Stock-Based Compensation
Stock-Based Compensation	14. Stock-Based Compensation In September 2016, the Company adopted the 2016 Equity Compensation Plan (the “2016 Plan”) and merged the 2014 Equity Compensation Plan (the “2014 Plan”) into the 2016 Plan on September 28, 2016. No additional grants were made thereafter under the 2014 Plan. Outstanding grants under the 2014 Plan will continue in effect according to their terms as in effect before the merger with the 2016 Plan, and the shares with respect to outstanding grants under the 2014 Equity Plan will be issued or transferred under the 2016 Plan. The 2016 Plan authorizes the issuance or transfer of up to the sum of the following: (1) 800,000 new shares, plus (2) the number of shares of common stock subject to outstanding grants under the 2014 Equity Plan as of the effective date of the 2016 Plan; provided, however, that the aggregate number of shares of the Company’s common stock that may be issued or transferred under the 2016 Plan pursuant to incentive stock options may not exceed 800,000. During the term of the 2016 Plan, the share reserve will automatically increase on the first trading day in January of each calendar year, beginning in calendar year 2017, by an amount equal to the lesser of 5% of the total number of outstanding shares of common stock on the last trading day in December of the prior calendar year or such other number set by the Board. During 2017, the Board approved an increase of 831,423 shares to the share reserve. As of September 30, 2017, 459,368 shares were available for future grants under the 2016 Plan. The option price per share cannot be less than the fair market value of a share on the date the option was granted, and in the case of incentive stock options granted to an employee owning more than 10% of the total combined voting power of all classes of stock of the Company, the option price shall not be less than 110% of the fair market value of Company stock on the date of grant. Stock option grants under the Plan generally expire 10 years from the date of grant, other than incentive stock option grants to 10% shareholders, which have a 5 year term, 90 days after termination, or one year after the date of death or termination due to disability. Stock options generally vest over a period of four years, with 25% of the options becoming exercisable on the one-year anniversary of the commencement date and the remaining shares vesting monthly thereafter for 36 months in equal installments of 2.08% per month. Employee Restricted Common Stock On September 28, 2016, the Board granted 700,386 shares of restricted common stock to certain Company employees, including executive officers, under the 2014 Plan, prior to merging it with the 2016 Plan, pursuant to a special equity award pool previously approved by the Board which was made immediately prior to the effectiveness of the Company's registration statement filed in connection with the Company's IPO. The value of the grants is based on the IPO price of $12.00 per share and the related non-cash compensation expense was being recognized ratably over the vesting period from the date of grant through May 31, 2017, when the shares underlying the grant were scheduled to fully vest. For the nine months ended September 30, 2017, $5,159 of expense was recognized related to this grant. No expense was recognized for the three months ended September 30, 2017. For the three and nine months ended September 30, 2016, $102 of expense was recognized related to this grant. As of September 30, 2017, there was no unrecognized compensation expense related to this grant. On June 12, 2017, the Company entered into an amendment with each recipient of this grant to amend the vesting date from May 31, 2017 to May 31, 2018. On August 3, 2017, the Board granted 20,000 shares of restricted common stock to a non-executive employee of the Company, pursuant to the 2016 Plan, which will vest in four substantially equal annual installments over the four years following the grant date. The value of the grant is based on the grant date fair value of the Company’s common stock of $14.56 per share. For the three and nine months ended September 30, 2017, $12 of expense was recognized related to this grant. As of September 30, 2017, there was unrecognized compensation expense of $279 related to this grant. Non-Employee Director Restricted Common Stock On September 28, 2016, the Company granted 22,260 shares of restricted common stock under the 2016 Plan to its non-employee directors, which represents both the initial and annual grants to such directors. The initial grant (“Initial Grant”) will vest in three substantially equal annual installments over three years following the grant date and the annual grant (“2016 Annual Grant”) will vest in full on the earlier of the next annual shareholder meeting or the one year anniversary of the grant date. The value of the grants is based on the IPO price of $12.00 per share. On March 8, 2017, the Company granted 5,212 shares of restricted common stock under the 2016 Plan to a newly appointed non-employee director, which represents such director’s initial grant and will vest in three substantially equal annual installments over three years following the grant date. The value of the grant is based on the grant date fair value of the Company’s common stock of $13.68 per share. On June 16, 2017, the Company granted 10,384 shares of restricted common stock (“2017 Annual Grant”) to its non-employee directors, which will vest in full on the earlier of the next annual shareholder meeting or the one year anniversary of the grant date. The value of the grant is based on the grant date fair value of the Company’s common stock of $13.54 per share. On June 16, 2017, the date of the Company’s annual shareholder meeting, the 2016 Annual Grant, which in the aggregate equaled 7,420 shares, fully vested and were no longer subject to forfeiture. In addition, on September 28, 2017, 4,944 shares of the Initial Grant vested and were no longer subject to forfeiture. For the three and nine months ended September 30, 2017, $56 and $165 of expense was recognized related to these non-employee director grants, respectively. For the three and nine months ended September 30, 2016, $1 of expense was recognized related to these grants. As of September 30, 2017, there was unrecognized compensation expense of $276 related to these grants. Stock Options The Company recorded $871 and $120 of stock-based compensation expense related to the vesting of employee and non-employee stock options for the three months ended September 30, 2017 and 2016, respectively. The Company recorded $2,440 and $378 of stock-based compensation expense related to the vesting of employee and non-employee stock options for the nine months ended September 30, 2017 and 2016, respectively. The estimated fair value of options granted was calculated using a Black-Scholes option-pricing model. The computation of expected life for employees was determined based on the simplified method. The risk-free rate is based on the U.S. Treasury security with terms equal to the expected time of exercise as of the grant date. The Company's common stock had not been publicly traded until the IPO commenced on September 29, 2016; therefore, expected volatility is based on the historical volatilities of selected public companies whose services are comparable to that of the Company. The table below sets forth the weighted average assumptions for employee grants during the nine months ended September 30, 2017 and 2016: Nine Months Ended September 30, Valuation assumptions: 2017 2016 Expected volatility 61.00 % 59.00 % Expected term (years) 6.03 6.08 Risk-free interest rate 2.21 % 1.49 % Dividend yield — — The weighted average grant date fair value of employee options granted during the nine months ended September 30, 2017 and 2016 was $8.13 and $7.29 per share, respectively. The following table summarizes stock option activity under the 2016 Plan for the nine months ended September 30, 2017: Weighted Weighted average average remaining Aggregate Number exercise contractual intrinsic of shares price term value Outstanding at December 31, 2016 3,059,690 $ 5.14 Granted 1,044,556 14.43 Exercised (1,054,764) 3.21 Forfeited (49,629) 10.52 Outstanding at September 30, 2017 $ 8.97 $ Options vested and expected to vest at September 30, 2017 2,999,853 $ 8.97 7.3 $ 53,340 Exercisable at September 30, 2017 1,393,742 $ 3.37 5.3 $ 32,572 Included within the above table are 150,212 non-employee options outstanding as of September 30, 2017, of which 345 are unvested as of September 30, 2017 and therefore subject to remeasurement. The aggregate intrinsic value of stock options is calculated as the difference between the exercise price of the stock options and the Company’s closing stock price or estimated fair value on the last trading day of the fiscal quarter for those stock options that had exercise prices lower than the fair value of the Company's common stock. This amount changes based on the fair market value of the Company’s stock. The total intrinsic value of options exercised during the nine months ended September 30, 2017 and 2016 was $11,665 and $832, respectively. As of September 30, 2017, there was $10,022 of total unrecognized compensation cost related to nonvested stock options granted under the 2016 Plan, which is expected to be recognized over a weighted average period of 2.9 years. Cash received from option exercises for the nine months ended September 30, 2017 was $194. During the nine months ended September 30, 2017, 362,440 shares of common stock were delivered by option holders as payment for the exercise price and employee payroll taxes owed for the exercise of 956,327 stock options with a gross exercise value of $3,187. During the nine months ended September 30, 2016, 7,930 shares of common stock were delivered by option holders as payment for the exercise of 71,150 stock options with a gross exercise value of $104. No cash was received from the exercise of stock options for the nine months ended September 30, 2016. The Company recorded total stock-based compensation expense for the three and nine months ended September 30, 2017 and 2016 in the following expense categories of its consolidated statement of operations: Three Months Ended Nine Months Ended September 30, September 30, 2017 2016 2017 2016 Cost of revenue - product $ 138 $ 27 $ 359 $ 85 Cost of revenue - service 91 7 203 21 Research and development 195 9 515 30 Sales and marketing 158 21 440 65 General and administrative 357 159 6,259 280 $ 939 $ 223 $ 7,776 $ 481

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Sep. 30, 2017
Fair Value Measurements
Fair Value Measurements	15. Fair Value Measurements The Company’s financial instruments consist of accounts receivable, accounts payable, accrued expenses, acquisition-related consideration payable, acquisition-related contingent consideration, and long-term debt. The carrying values of accounts receivable, accounts payable and accrued expenses are representative of their fair value due to the relatively short-term nature of those instruments. The carrying value of the Company’s long-term debt approximates fair value based on the terms of the debt. The Company has classified liabilities measured at fair value on a recurring basis at September 30, 2017 and December 31, 2016 as follows: Fair Value Measurement at Reporting Date Using Balance as of Level 1 Level 2 Level 3 September 30, 2017 Liabilities Acquisition-related contingent consideration - short-term — — 15,224 Acquisition-related contingent consideration - long-term — — 13,652 $ — $ — $ $ 28,876 Fair Value Measurement at Reporting Date Using Balance as of Level 1 Level 2 Level 3 December 31, 2016 Liabilities Acquisition-related contingent consideration - short-term $ — $ — $ 1,493 $ 1,493 Acquisition-related contingent consideration - long-term — — 1,515 1,515 $ — $ — $ 3,008 $ 3,008 Acquisition-related contingent consideration is measured at fair value on a recurring basis using unobservable inputs, hence these instruments represent Level 3 measurements within the fair value hierarchy. The acquisition-related contingent consideration liability represents the estimated fair value of the additional cash and equity consideration payable that is contingent upon the achievement of certain financial and performance milestones. The SRx acquisition-related contingent consideration was recorded at the estimated fair value at the acquisition date of September 6, 2017. The Company, with the assistance of a third-party appraiser, utilized a Monte Carlo simulation to derive at preliminary estimates of the contingent consideration payments. The fair value of the SRx acquisition-related contingent consideration was calculated to be $27,313 as of September 30, 2017. The fair value of the Medliance contingent consideration was calculated to be $1,563 as of September 30, 2017. The changes in fair value of the Company’s acquisition-related contingent consideration for the nine months ended September 30, 2017 was as follows: Balance at December 31, 2016 3,008 Acquisition date fair value of SinfoníaRx contingent consideration 26,406 Fair value of cash consideration paid (1,498) Adjustments to fair value measurement 960 Balance at September 30, 2017 $ 28,876

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2017
Commitments and Contingencies
Commitments and Contingencies	16. Commitments and Contingencies The Company is not currently involved in any significant claims or legal actions that, in the opinion of management, will have a material adverse impact on the Company. As of September 30, 2017 and December 31, 2016, the Company was contingently liable for $500 under an outstanding letter of credit related to the Company’s lease agreement for the office space in Moorestown, NJ. See Note 10 for additional information.

Retirement Plan

Retirement Plan	9 Months Ended
	Sep. 30, 2017
Retirement Plan
Retirement Plan	17. Retirement Plan The Company has established a 401(k) plan that qualifies as a defined contribution plan under Section 401 of the Internal Revenue Code. The Company’s contributions to this plan are based on a percentage of eligible employees’ plan year earnings, as defined. The Company made contributions to participants’ accounts totaling $194 and $128 during the three months ended September 30, 2017 and 2016, respectively. The Company made contributions to participants’ accounts totaling $478 and $230 during the nine months ended September 30, 2017 and 2016, respectively.

Employment Agreements

Employment Agreements	9 Months Ended
	Sep. 30, 2017
Employment Agreements and Incentive Arrangements
Employment Agreements	18. Employment Agreements and Incentive Arrangements On April 25, 2017, the Company entered into employment agreements with each of the Company’s named executive officers . The employment agreements provide for, among other things, salary, incentive compensation, payments in the event of termination of the executives upon the occurrence of a change in control, and restrictive covenants pursuant to which the executives have agreed to refrain from competing with the Company or soliciting the Company’s employees or customers for a period following the executive’s termination of employment. Each employment agreement is effective as of April 1, 2017, has an initial three year term and will automatically renew each anniversary thereafter. On April 25, 2017, the Company’s Board also adopted the Annual Incentive Plan, effective as of January 1, 2017, which formalizes the Company’s annual short-term incentive program and does not represent a new compensation program for the named executive officers. The Annual Incentive Plan provides pay for performance incentive compensation to the Company’s employees, including its named executive officers, rewarding them for their contributions to the Company with cash incentive compensation based on attainment of pre-determined corporate and individual performance goals, as applicable.

Related-Party Transactions

Related-Party Transactions	9 Months Ended
	Sep. 30, 2017
Related-Party Transactions
Related-Party Transactions	19. Related-Party Transactions During 2016, the Company engaged Tunstall Consulting, a corporate financial planning company, to provide professional services related to obtaining a prior credit facility. Tunstall Consulting is owned and operated by a member of the Board. Costs incurred by the Company for professional services provided by the related party were $104 and were recorded as deferred financing costs during 2016, which were subsequently fully amortized when the facility was repaid in full during the third quarter of 2016.

Summary of Significant Accoun26

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2017
Summary of Significant Accounting Policies
Basis of Presentation	(a) Basis of Presentation The accompanying unaudited consolidated financial statements of the Company have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) and applicable rules and regulations of the Securities and Exchange Commission (the “SEC”) regarding interim financial reporting. The unaudited interim consolidated financial statements have been prepared on the same basis as the annual audited consolidated financial statements and, in the opinion of management, reflect all adjustments ( consisting of normal recurring accruals and adjustments) , necessary for the fair statement of the Company's interim consolidated financial position for the periods indicated. The interim results for the three and nine months ended September 30, 2017 are not necessarily indicative of results to be expected for the year ending December 31, 2017, any other interim periods, or any future year or period. As such, the information included in this quarterly report on Form 10-Q should be read in conjunction with the consolidated financial statements and accompanying notes included in the Company’s annual report as filed on Form 10-K.
Liquidity	(b) Liquidity The Company's unaudited consolidated financial statements have been prepared on the basis of continuity of operations, realization of assets and the satisfaction of liabilities in the ordinary course of business. Management believes that the Company's cash on hand of $5,939 as of September 30, 2017, cash flows from operations and borrowing availability under the Amended and Restated 2015 Revolving Line are sufficient to fund the Company's planned operations through at least December 31, 2018.
Use of Estimates	(c) Use of Estimates The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates or assumptions.
Revenue Recognition	(d) Revenue Recognition The Company recognizes revenue from product sales or services rendered when (i) persuasive evidence of an arrangement exists, (ii) services have been rendered, (iii) the price to its client is fixed or determinable and (iv) collectability is reasonably assured. When the Company enters into arrangements with multiple deliverables, it applies the accounting guidance for revenue arrangements with multiple deliverables and evaluates each deliverable to determine whether it represents a separate unit of accounting based on the following criteria: (i) whether the delivered item has value to the customer on a standalone basis, and (ii) if the contract includes a general right of return relative to the delivered item, delivery or performance of the undelivered item(s) is considered probable and substantially in the control of the Company. Revenue is allocated to each element in an arrangement based on a selling price hierarchy. The selling price for a deliverable is based on estimated selling prices ("ESP") as vendor specific objective evidence or third party evidence is not available. The Company establishes ESP for the elements of its arrangements based upon its pricing practices and class of customers. The stated prices for the various deliverables of the Company's contracts are consistent across classes of customers. Product Revenue The Company enters into multiple-element arrangements with healthcare organizations to provide software enabled medication risk management solutions. Under these contracts, revenue is generated through the components listed below. Prescription medication revenue The Company sells prescription medications directly to healthcare organizations through its prescription fulfillment pharmacies. Prescription medication fees are based upon the prices stated in customer contracts for the prescription and include a dispensing fee. Prescription medication revenue, including dispensing fees, is recognized when the product is shipped to the customer. Prescription medications are considered a separate unit of accounting. Per member per month fees — medication risk management services The Company receives a fixed monthly administrative fee for each member in the program contracted for medication risk management services. This fee, which is included in product revenue in the consolidated statement of operations, is recognized on a monthly basis as medication risk management services are provided. The services associated with the per member per month fees are considered a separate unit of accounting. Service Revenue The Company provides medication risk management services utilizing the Medication Risk Mitigation Matrix (“MRM Matrix”) technology alone, without the related fulfillment services, which are referred to as MRM Service Contracts. The Company began entering into these MRM Service Contracts in the third quarter of 2016. The Company’s MRM Service Contracts also include services provided by the SinfoníaRx business, which was acquired on September 6, 2017. The SinfoníaRx business provides Medication Therapy Management (“MTM”) technology and services for Medicare, Medicaid, and commercial health plans, which are referred to as MTM Contracts. See Note 4 for additional information about the acquisition of the SinfoníaRx business. The Company also enters into contracts with healthcare organizations to provide (i) risk adjustment and (ii) pharmacy cost management services, which include training client staff and providers about documentation and diagnosis coding, analyzing clients' data collection and submission processes, and delivering meaningful analytics for understanding reimbursement complexities. Under the MRM Service Contracts, MTM Contracts and risk adjustment contracts, there are generally three revenue generating components: Set up fees: The Company's contracts for Medication Risk Mitigation (“MRM”) and risk adjustment services often require customers to pay non-refundable set up fees, which are deferred and recognized over the estimated term of the contract. These fees are charged at the beginning of the customer relationship as compensation for the Company's efforts to prepare the customer and configure its system for the data collection process. The set up activities do not represent a separate unit of accounting as they do not have value apart from the broader MRM Service Contracts, MTM Contracts and risk adjustment contracts. Incremental direct costs associated with such set up activities are also deferred and amortized over the shorter of the estimated customer life or stated contract period. Per member per month fees The Company receives a fixed monthly fee for each member in the respective programs. These services represent a separate unit of accounting and are offered independently from any other services. Revenue for these services is recognized each month as the services are performed. Hourly consulting fees or transactional based fees The Company sometimes contracts with customers to perform various other services. Such services are billed on a time and materials basis, at agreed hourly rates, or on a per transaction basis. Consulting services represent a separate unit of accounting and are offered independently from any other services. Revenue for these services is recognized as time is incurred on the project. The Company's pharmacy cost management services include subscription revenue from customers and revenues from drug manufacturers for the sale of drug utilization data. Subscription revenue is recognized monthly as either a flat fee or as a percentage of monthly transactions incurred. Data and statistics fees from drug manufacturers are recognized as revenue when received due to the unpredictable nature of the payments and because fees are not fixed and determinable until received.
Cost of Product Revenue	(e) Cost of Product Revenue Cost of product revenue includes all costs directly related to the medication risk management offering, including costs relating to the Company's pharmacists' collaboration on a patient's medication management, clinical analysis of the results and, when necessary, offering guidance to the prescriber based upon the review of the medication risk mitigation matrix and the individual patient's medical history, as well as the fulfillment and distribution of prescription drugs. Costs consist primarily of the purchase price of the prescription drugs the Company dispenses, expenses to package, dispense and distribute prescription drugs, expenses associated with the Company's medication care plan support centers and prescription fulfillment centers, including employment costs and stock-based compensation, and expenses related to the hosting of the Company's technology platform. Such costs also include direct overhead expenses, as well as allocated miscellaneous overhead costs. The Company allocates miscellaneous overhead costs among functions based on employee headcount.
Cost of Service Revenue	(f) Cost of Service Revenue Cost of service revenue includes all labor costs, including stock-based compensation expense, directly related to the risk adjustment and pharmacy cost management services and expenses for claims processing, technology services and overhead costs. In addition, service costs include all costs directly related to servicing the Company’s MRM Service Contracts and MTM Contracts, which primarily consist of labor costs, consultant fees, technology services and overhead costs.
Recent Accounting Pronouncements	(g) R ecent Accounting Pronouncements In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers ("ASU 2014-09") and has subsequently issued a number of amendments to ASU 2014-09. ASU 2014-09, as amended, represents a comprehensive new revenue recognition model that requires a company to recognize revenue to depict the transfer of promised goods or services to clients in an amount that reflects the consideration to which the Company expects to be entitled to receive in exchange for those goods or services. ASU 2014-09 sets forth a new five-step revenue recognition model which replaces the prior revenue recognition guidance in its entirety and is intended to eliminate numerous industry-specific pieces of revenue recognition guidance that have historically existed. For public companies, ASU 2014-09 is effective for annual reporting periods beginning after December 15, 2017 and interim reporting periods within that reporting period. Early adoption is permitted for annual reporting periods beginning after December 15, 2016; however, the Company does not intend to early adopt the new standard. Companies may use either a full retrospective or a modified retrospective approach to adopt ASU 2014-09. The Company intends to adopt the new standard effective January 1, 2018 but has not yet determined which transition method will be used. The Company is currently analyzing significant contracts with customers to determine the impact of the adoption of ASU 2014-09 on the Company’s consolidated financial statements and disclosures. The Company will continue to assess all potential impacts of the standard on existing and new customer contracts during 2017 and on the Company’s processes and internal controls over financial reporting. A final evaluation of the impact of the adoption of the new standard is expected to be completed by the end of 2017 . In July 2015, the FASB issued ASU 2015-11, Inventory (Topic 330): Simplifying the Measurement of Inventory ("ASU 2015-11"), which simplifies the subsequent measurement of inventories by replacing the current lower of cost or market test with a lower of cost and net realizable value test. ASU 2015-11 is effective for public business entities for fiscal years beginning after December 15, 2016, and interim periods within those fiscal years. Early adoption is permitted. The Company has adopted ASU 2015-11 effective January 1, 2017. The adoption of this standard did not have any impact on the Company's consolidated financial statements. In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) ("ASU 2016-02"). The new standard establishes a right-of-use ("ROU") model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. ASU 2016-02 is effective for annual periods beginning after December 15, 2018, including interim periods within those annual periods, with early adoption permitted. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. The Company is currently evaluating the potential impact of the adoption of this standard and anticipates that this standard will have a material impact on the Company’s consolidated financial statements, as all long-term leases will be capitalized on the consolidated balance sheet. In March 2016, the FASB issued ASU 2016-09, Compensation — Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting ("ASU 2016-09"). The amendments in this update simplify certain aspects related to how share-based payments are accounted for and presented in the financial statements. The new guidance requires excess tax benefits and tax deficiencies be recorded as an income tax benefit or expense in the statement of operations when the awards vest or are settled and as operating cash flows when realized. The excess tax benefits are recognized regardless of whether the benefit reduces income taxes payable in the current period. It also allows an employer to repurchase more of an employee's shares than it can today for tax withholding purposes without triggering liability accounting and to make a policy election to account for forfeitures as they occur. ASU 2016-09 is effective for fiscal years beginning after December 15, 2016, and interim periods within those fiscal years. The Company adopted ASU 2016-09 effective January 1, 2017. The Company elected to record forfeitures as they occur. There was no impact of this election because prior to the adoption the Company’s historical forfeitures were de minimus. The adoption of this new standard resulted in the recognition of a tax benefit in the amount of $2,830 in the consolidated statement of operations related to tax windfall benefits generated during the nine months ended September 30, 2017. In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments ("ASU 2016-15"). ASU 2016-15 provides new guidance to reduce diversity in practice in how certain transactions are classified in the statement of cash flows. ASU 2016-15 is effective for financial statements issued for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. The Company is currently evaluating the potential impact of the adoption of ASU 2016-15 on the Company's consolidated financial statements. In January 2017, the FASB issued Accounting Standards Update No. 2017-01, Business Combinations (“ASU 2017-01”). ASU 2017-01 provides guidance for evaluating whether a set of transferred assets and activities (the “set”) should be accounted for as an acquisition of a business or group of assets. The guidance provides a screen to determine when a set does not qualify to be a business. When substantially all of the fair value of the gross assets acquired (or disposed of) is concentrated in an identifiable asset or a group of similar assets, the set is not a business. Also to be considered a business, the set would have to include an input and a substantive process that together significantly contribute to the ability to create outputs. ASU 2017-01 is effective for financial statements issued for fiscal years beginning after December 15, 2017. The Company is currently evaluating the potential impact of the adoption of ASU 2017-01 on the Company's consolidated financial statements. In January 2017, the FASB issued ASU No. 2017-04, Intangibles – Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment ("ASU 2017-04"). ASU 2017-04 simplifies the accounting for goodwill impairment by eliminating the requirement to calculate the implied fair value of goodwill to measure an impairment charge. Instead, entities will be required to record an impairment charge based on the excess of a reporting unit’s carrying value over its fair value. ASU 2017-04 is effective for financial statements issued for fiscal years beginning after December 15, 2019. The Company is currently evaluating the potential impact of the adoption of ASU 2017-04 on the Company's consolidated financial statements. In May 2017, the FASB issued ASU No. 2017-09, Compensation – Stock Compensation (Topic 718): Scope of Modification Accounting (“ASU 2017-09”). ASU 2017-09 amends the scope of modification accounting for share-based payment arrangements. The guidance requires modification accounting only if the fair value, vesting conditions, or the classification of the award (as equity or liability) changes as a result of a change in terms or conditions. ASU 2017-09 is effective for financial statements issued for fiscal years beginning after December 15, 2017. The Company is currently evaluating the potential impact of the adoption of ASU 2017-09 on the Company's consolidated financial statements.
Net Income (Loss) per Share	Basic net income (loss) per share is computed by dividing net income (loss) attributable to common stockholders by the weighted average number of shares of common stock of the Company outstanding during the period. The Company computed net income (loss) per share of common stock using the treasury stock method for the three and nine months ended September 30, 2017, and using the two-class method required for participating securities for the three and nine months ended September 30, 2016. The Company considered its redeemable convertible preferred stock to be participating securities as the holders of the preferred stock were entitled to receive a dividend in the event that a dividend was paid on common stock. Diluted net income (loss) per share is computed by dividing net income (loss) attributable to common stockholders by the weighted average number of shares of common stock during the period plus the impact of dilutive securities, to the extent that they are not anti-dilutive.

Net Income (Loss) per Share (Ta

Net Income (Loss) per Share (Tables)	9 Months Ended
	Sep. 30, 2017
Net Income (Loss) per Share
Schedule of calculation of basic and diluted net income (loss) per share	Three Months Ended Nine Months Ended September 30, September 30, 2017 2016 2017 2016 Numerator: Net income (loss) $ 7,695 $ (142) $ 3,350 $ (219) Decretion of redeemable convertible preferred stock — 2,641 — 2,439 Undistributed income attributable to redeemable convertible preferred stockholders — (1,271) — (1,140) Net income (loss) attributable to common stockholders, basic $ 7,695 $ 1,228 $ 3,350 $ 1,080 Decretion of redeemable convertible preferred stock — (2,641) — (2,439) Revaluation of warrant liability, net of tax — (661) — (675) Adjustment to undistributed income attributable to redeemable convertible preferred stockholders — 1,271 — 1,140 Net income (loss) attributable to common stockholders, diluted $ 7,695 $ (803) $ 3,350 $ (894) Denominator (basic): Weighted average shares of common stock outstanding, basic 16,699,102 4,918,885 16,483,169 4,817,285 Denominator (diluted): Weighted average shares of common stock outstanding 16,699,102 4,918,885 16,483,169 4,817,285 Effect of potential dilutive securities: Weighted average dilutive effect of stock options 1,235,883 — 1,308,202 — Weighted average dilutive effect of restricted shares 711,046 607,988 — Weighted average dilutive effect of common shares from warrants — — 12,441 — Dilutive effect from preferred stock and preferred stock warrants assuming conversion — 5,414,838 — 5,414,765 Weighted average shares of common stock outstanding, diluted 18,646,031 10,333,723 18,411,800 10,232,050 Net income per share attributable to common stockholders, basic $ 0.46 $ 0.25 $ 0.20 $ 0.22 Net income (loss) per share attributable to common stockholders, diluted $ 0.41 $ (0.08) $ 0.18 $ (0.09)
Schedule of shares excluded from the calculation of diluted net loss per share attributable to common stockholders	Three Months Ended Nine Months Ended September 30, September 30, 2017 2016 2017 2016 Stock options to purchase common stock — 2,723,193 — 2,723,193 Restricted stock — 722,646 — 722,646 Common stock warrants — 213,806 — 213,806 — 3,659,645 — 3,659,645

Acquisitions (Tables)

Acquisitions (Tables)	9 Months Ended
	Sep. 30, 2017
Schedule of proforma results	Three Months Ended Three Months Ended Nine Months Ended Nine Months Ended September 30, September 30, September 30, September 30, 2017 2016 2017 2016 Revenue $ 39,420 $ 31,266 $ 112,079 $ 85,336 Net loss (727) (1,332) (5,098) (4,259) Net income (loss) per share attributable to common stockholders, basic (0.04) 0.12 (0.30) (0.32) Net loss per share attributable to common stockholders, diluted (0.04) (0.17) (0.30) (0.44)
SinfoniaRx
Schedule of purchase price consideration	Cash consideration at closing, net of post-closing adjustments $ Stock consideration at closing 11,541 Estimated fair value of contingent consideration 26,406 Total fair value of acquisition consideration $ 72,617
Schedule of allocation of the purchase price based on the estimated fair values of the assets acquired and liabilities	Cash $ 218 Accounts receivable 8,309 Prepaid expenses and other current assets 1,001 Property and equipment 1,419 Other assets 94 Trade name 4,429 Developed technology 12,640 Client relationships 19,579 Non-competition agreement 4,497 Goodwill 41,439 Total assets acquired $ 93,625 Accrued expenses and other liabilities (2,667) Trade accounts payable (8,769) Debt assumed (675) Deferred income tax liability (8,897) Total purchase price, including contingent consideration of $26,406 $ 72,617

Software Development Costs (Tab

Software Development Costs (Tables)	9 Months Ended
	Sep. 30, 2017
Software Development Costs
Schedule of capitalized software costs	September 30, 2017 December 31, 2016 Software development costs $ 8,652 $ 6,501 Less: accumulated amortization (4,388) (3,151) Software development costs, net $ 4,264 $ 3,350 Capitalized software costs not yet subject to amortization $ 2,421 $ 911

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	9 Months Ended
	Sep. 30, 2017
Goodwill and Intangible Assets
Schedule of goodwill	Balance at January 1, 2017 $ 21,686 Goodwill from 2017 acquisition 41,439 Balance at September 30, 2017 $ 63,125
Schedule of intangible assets	Weighted Average Amortization Period Accumulated Intangible (in years) Gross Value Amortization Assets, net September 30, 2017 Trade names 8.48 $ 6,369 $ (1,102) $ 5,267 Client relationships 8.56 34,263 (4,528) Non-competition agreements 4.95 5,149 (465) 4,684 Developed technology 7.87 26,140 (2,504) Domain name 10.00 29 (4) 25 Total intangible assets $ 71,950 $ (8,603) $ Weighted Average Amortization Period Accumulated Intangible (in years) Gross Value Amortization Assets, net December 31, 2016 Trade names 5.00 $ 1,940 $ (791) $ 1,149 Client relationships 10.02 14,684 (3,289) 11,395 Non-competition agreements 4.64 652 (326) 326 Developed technology 7.76 13,500 (1,101) 12,399 Domain name 10.00 29 (1) 28 Total intangible assets $ 30,805 $ (5,508) $ 25,297
Schedule of estimated amortization expense	Years Ending December 31, 2017 (October 1 - December 31) $ 2,398 2018 9,557 2019 9,115 2020 8,776 2021 8,763 Thereafter 24,738 Total estimated amortization expense $ 63,347

Accrued Expenses and Other Li31

Accrued Expenses and Other Liabilities (Tables)	9 Months Ended
	Sep. 30, 2017
Accrued Liabilities and Other Liabilities
Schedule of accrued expenses and other liabilities	September 30, 2017 December 31, 2016 Employee related expenses $ 4,634 $ 1,174 Deferred revenue 1,526 851 Contract labor 733 — Interest 115 16 Deferred rent 150 13 Professional fees 169 — Income taxes payable 281 27 Other expenses 493 78 Total accrued expenses and other liabilities $ 8,101 $ 2,159

Lines of Credit and Long-Term32

Lines of Credit and Long-Term Debt (Tables)	9 Months Ended
	Sep. 30, 2017
Lines of Credit and Long-Term Debt
Schedule of capital lease obligations	September 30, 2017 December 31, 2016 Capital leases $ 1,946 $ 1,746 Less current portion, net (927) (674) Total capital leases, less current portion, net $ 1,019 $ 1,072
Schedule of maturities of long-term debt payable	Total long-term debt Remainder of 2017 $ 293 2018 1,065 2019 725 2020 116 2021 5 2,204 Less amount representing interest (258) Present value of payments 1,946 Less current portion (927) Total long-term debt, net of current portion $ 1,019

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2017
Stock-Based Compensation
Schedule of weighted average assumptions for employee grants	Nine Months Ended September 30, Valuation assumptions: 2017 2016 Expected volatility 61.00 % 59.00 % Expected term (years) 6.03 6.08 Risk-free interest rate 2.21 % 1.49 % Dividend yield — —
Summary of stock option activity	Weighted Weighted average average remaining Aggregate Number exercise contractual intrinsic of shares price term value Outstanding at December 31, 2016 3,059,690 $ 5.14 Granted 1,044,556 14.43 Exercised (1,054,764) 3.21 Forfeited (49,629) 10.52 Outstanding at September 30, 2017 $ 8.97 $ Options vested and expected to vest at September 30, 2017 2,999,853 $ 8.97 7.3 $ 53,340 Exercisable at September 30, 2017 1,393,742 $ 3.37 5.3 $ 32,572
Schedule of recorded stock-based compensation expense related to stock options	Three Months Ended Nine Months Ended September 30, September 30, 2017 2016 2017 2016 Cost of revenue - product $ 138 $ 27 $ 359 $ 85 Cost of revenue - service 91 7 203 21 Research and development 195 9 515 30 Sales and marketing 158 21 440 65 General and administrative 357 159 6,259 280 $ 939 $ 223 $ 7,776 $ 481

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2017
Change in fair value
Schedule of classified liabilities measured at fair value on recurring basis	Fair Value Measurement at Reporting Date Using Balance as of Level 1 Level 2 Level 3 September 30, 2017 Liabilities Acquisition-related contingent consideration - short-term — — 15,224 Acquisition-related contingent consideration - long-term — — 13,652 $ — $ — $ $ 28,876 Fair Value Measurement at Reporting Date Using Balance as of Level 1 Level 2 Level 3 December 31, 2016 Liabilities Acquisition-related contingent consideration - short-term $ — $ — $ 1,493 $ 1,493 Acquisition-related contingent consideration - long-term — — 1,515 1,515 $ — $ — $ 3,008 $ 3,008
Acquisition related contingent consideration
Change in fair value
Schedule of reconciliation of liability measured at fair value on recurring basis using significant unobservable inputs (Level 3)	Balance at December 31, 2016 3,008 Acquisition date fair value of SinfoníaRx contingent consideration 26,406 Fair value of cash consideration paid (1,498) Adjustments to fair value measurement 960 Balance at September 30, 2017 $ 28,876

Nature of Business (Details)

Nature of Business (Details) - USD ($) $ / shares in Units, $ in Thousands	Oct. 04, 2016	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016
Initial Public Offering
Common stock authorized shares	100,000,000	100,000,000		100,000,000
Shares of common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001		$ 0.0001
Shares of undesignated preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001		$ 0.0001
Shares of undesignated preferred stock, authorized	10,000,000	10,000,000		10,000,000
Common stock warrants
Initial Public Offering
Number of shares issuable upon net exercise of outstanding warrants	463,589
Common Stock
Initial Public Offering
Redesignation of Class A and Class B common stock upon initial public offering (in shares)	5,583,405
Conversion of redeemable convertible preferred stock upon initial public offering (in shares)	5,089,436
Shares issued upon exercise of warrants (in shares)	202,061	28,431	210,817
IPO
Initial Public Offering
Issuance of common stock upon public offering (in shares)	4,300,000
Issuance price (in dollars per share)	$ 12
Proceeds from issuance of common stock under initial public offering, net of underwriting costs	$ 55,186
Underwriting discounts and commissions	$ 4,154
Underwriter option
Initial Public Offering
Issuance of common stock upon public offering (in shares)	645,000

Summary of Significant Accoun36

Summary of Significant Accounting Policies - Liquidity, Revenue and AR (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2017USD ($)item	Dec. 31, 2016USD ($)	Sep. 30, 2016USD ($)	Dec. 31, 2015USD ($)
Summary of Significant Accounting Policies
Cash on hand | $	$ 5,939	$ 4,345	$ 1,793	$ 2,026
Substantial doubt about going concern, within one year	false
Revenue Recognition
Number of revenue generating components | item	3

Summary of Significant Accoun37

Summary of Significant Accounting Policies - Recent Accounting Pronouncements (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Summary of Significant Accounting Policies
Income tax benefit, Tax windfall			$ 2,830
Income tax (benefit) expense	$ (8,105)	$ (164)	$ (7,845)	$ 11

Net Income (Loss) per Share - E

Net Income (Loss) per Share - EPS (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Numerator
Net income (loss)	$ 7,695	$ (142)	$ 3,350	$ (219)
Decretion of redeemable convertible preferred stock		2,641		2,439
Undistributed income attributable to redeemable convertible preferred stockholders		(1,271)		(1,140)
Net income (loss) attributable to common stockholders, basic	7,695	1,228	3,350	1,080
Decretion of redeemable convertible preferred stock		(2,641)		(2,439)
Revaluation of warrant liability, net of tax		(661)		(675)
Adjustment to undistributed income attributable to redeemable convertible preferred stockholders		1,271		1,140
Net income (loss) attributable to common stockholders, diluted	$ 7,695	$ (803)	$ 3,350	$ (894)
Denominator (basic):
Weighted average shares of common stock outstanding, basic	16,699,102	4,918,885	16,483,169	4,817,285
Denominator (diluted):
Weighted average shares of common stock outstanding, basic	16,699,102	4,918,885	16,483,169	4,817,285
Effect of potential dilutive securities:
Weighted average dilutive effect of common shares from warrants			12,441
Dilutive effect from preferred stock and preferred stock warrants assuming conversion		5,414,838		5,414,765
Weighted average shares of common stock outstanding, diluted	18,646,031	10,333,723	18,411,800	10,232,050
Net income per share attributable to common stockholders, basic (in dollars per share)	$ 0.46	$ 0.25	$ 0.20	$ 0.22
Net income (loss) per share attributable to common stockholders, diluted (in dollars per share)	$ 0.41	$ (0.08)	$ 0.18	$ (0.09)
Stock options
Effect of potential dilutive securities:
Weighted average dilutive effect of share-based awards	1,235,883		1,308,202
Restricted stock
Effect of potential dilutive securities:
Weighted average dilutive effect of share-based awards	711,046		607,988

Net Income (Loss) per Share - A

Net Income (Loss) per Share - Anti-dilutive Securities (Details) - shares	3 Months Ended	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2016
Securities excluded from the calculation of diluted net loss per share attributable to common stockholders
Amount of antidilutive securities excluded from computation of earnings per share	3,659,645	3,659,645
Employee stock options
Securities excluded from the calculation of diluted net loss per share attributable to common stockholders
Amount of antidilutive securities excluded from computation of earnings per share	2,723,193	2,723,193
Restricted stock
Securities excluded from the calculation of diluted net loss per share attributable to common stockholders
Amount of antidilutive securities excluded from computation of earnings per share	722,646	722,646
Common stock warrants
Securities excluded from the calculation of diluted net loss per share attributable to common stockholders
Amount of antidilutive securities excluded from computation of earnings per share	213,806	213,806

Net Income (Loss) per Share - I

Net Income (Loss) per Share - IPO (Details)	Oct. 04, 2016$ / sharesshares
IPO
Initial Public Offering
Issuance of common stock upon public offering (in shares)	4,300,000
Issuance price (in dollars per share) | $ / shares	$ 12
Underwriter option
Initial Public Offering
Issuance of common stock upon public offering (in shares)	645,000

Acquisitions - SinfoniaRx (Deta

Acquisitions - SinfoniaRx (Details) $ / shares in Units, $ in Thousands	Sep. 06, 2017USD ($)D$ / sharesshares	Sep. 30, 2017USD ($)	Sep. 30, 2016USD ($)	Sep. 30, 2017USD ($)	Sep. 30, 2016USD ($)	Dec. 31, 2016USD ($)
Allocation of the purchase price based on the estimated fair values of the assets acquired and liabilities assumed
Goodwill		$ 63,125		$ 63,125		$ 21,686
Service revenue		8,647	$ 3,443	19,222	$ 8,017
Net income (loss)		7,695	$ (142)	$ 3,350	$ (219)
Trade names
Allocation of the purchase price based on the estimated fair values of the assets acquired and liabilities assumed
Weighted average amortization period				8 years 5 months 23 days		5 years
Developed technology
Allocation of the purchase price based on the estimated fair values of the assets acquired and liabilities assumed
Weighted average amortization period				7 years 10 months 13 days		7 years 9 months 4 days
Non-competition agreement intangible asset
Allocation of the purchase price based on the estimated fair values of the assets acquired and liabilities assumed
Weighted average amortization period				4 years 11 months 12 days		4 years 7 months 21 days
SinfoniaRx
Acquisition
Cash consideration	$ 35,000
Percentage of contingent consideration payable in cash	50.00%
Percentage of contingent consideration payable in stock	50.00%
Aggregate value of contingent consideration	$ 130,000
Issuance of common stock (in shares) | shares	520,821
Issuance price (in dollars per share) | $ / shares	$ 19.20
Number of trading days | D	20
Direct acquisition costs	$ 949
Purchase price consideration
Cash consideration at closing, net of post-closing adjustments	34,670
Stock consideration at closing	11,541
Estimated fair value of contingent consideration	26,406
Total fair value of acquisition consideration	72,617
Allocation of the purchase price based on the estimated fair values of the assets acquired and liabilities assumed
Cash	218
Accounts receivable	8,309
Prepaid and other current assets	1,001
Property and equipment	1,419
Other assets	94
Goodwill	41,439
Total assets acquired	93,625
Accrued expenses and other liabilities	(2,667)
Trade accounts payable	(8,769)
Debt assumed	(675)
Deferred income tax liability	(8,897)
Total purchase price, including contingent consideration of $26,406	72,617
Contingent consideration	$ 26,406
Weighted average amortization period	7 years 8 months 5 days
Service revenue		2,638		$ 2,638
Net income (loss)		$ 285		$ 285
SinfoniaRx | Maximum
Acquisition
Cash consideration	$ 35,000
SinfoniaRx | Trade names
Allocation of the purchase price based on the estimated fair values of the assets acquired and liabilities assumed
Intangible assets	$ 4,429
Weighted average amortization period	10 years
SinfoniaRx | Developed technology
Allocation of the purchase price based on the estimated fair values of the assets acquired and liabilities assumed
Intangible assets	$ 12,640
Weighted average amortization period	8 years
SinfoniaRx | Client relationships intangible asset
Allocation of the purchase price based on the estimated fair values of the assets acquired and liabilities assumed
Intangible assets	$ 19,579
Weighted average amortization period	7 years 6 months 22 days
SinfoniaRx | Non-competition agreement intangible asset
Allocation of the purchase price based on the estimated fair values of the assets acquired and liabilities assumed
Intangible assets	$ 4,497
Weighted average amortization period	5 years

Acquisitions - IntermedRx (Deta

Acquisitions - IntermedRx (Details) - USD ($) $ in Thousands	Sep. 15, 2017	Nov. 03, 2016	Sep. 15, 2016	Nov. 03, 2017	Sep. 30, 2017	Dec. 31, 2016	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Acquisition
Acquisition-related consideration payable					$ 50	$ 568		$ 50
Quebec Inc.
Acquisition
Cash consideration	$ 550	$ 6,000	$ 1,000	$ 50		$ 4,400
Deferred stock consideration			5,000
Equity consideration (in shares)						395,407
Deferred acquisition cash consideration			5,000
Acquisition-date fair value of deferred cash consideration			$ 4,955
Cost of debt (as a percent)			7.80%
Discount			$ 45
Amortization of discount					10		$ 2	32	$ 2
Acquisition-related consideration payable					$ 50			$ 50

Acquisitions - Pro forma (Detai

Acquisitions - Pro forma (Details) - Quebec Inc and SinfoniaRx - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Acquisition
Revenue	$ 39,420	$ 31,266	$ 112,079	$ 85,336
Net loss	$ (727)	$ (1,332)	$ (5,098)	$ (4,259)
Net income (loss) per share attributable to common stockholders, basic (in dollars per share)	$ (0.04)	$ 0.12	$ (0.30)	$ (0.32)
Net loss per share attributable to common stockholders, diluted (in dollars per share)	$ (0.04)	$ (0.17)	$ (0.30)	$ (0.44)
Pro forma adjustment
Acquisition
Direct acquisition costs excluded	$ 855		$ 949

Property and Equipment (Details

Property and Equipment (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Property and Equipment
Depreciation and amortization expense	$ 2,166	$ 1,276	$ 5,730	$ 3,415
Property and equipment
Property and Equipment
Depreciation and amortization expense	$ 542	$ 359	$ 1,396	$ 889

Software Development Costs (Det

Software Development Costs (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016
Software Development Costs
Gross capitalized software costs	$ 8,652		$ 8,652		$ 6,501
Less: accumulated amortization	(4,388)		(4,388)		(3,151)
Software development costs, net	4,264		4,264		3,350
Capitalized software costs not yet subject to amortization	2,421		2,421		$ 911
Amortization expense	$ 426	$ 302	$ 1,237	$ 757

Goodwill and Intangible Asset46

Goodwill and Intangible Assets - Goodwill (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2017USD ($)
Goodwill and related changes
Goodwill at beginning of period	$ 21,686
Goodwill from 2017 acquisition	41,439
Goodwill at end of period	$ 63,125

Goodwill and Intangible Asset47

Goodwill and Intangible Assets - Intangible assets (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016
Intangible Assets
Gross Value	$ 71,950		$ 71,950		$ 30,805
Accumulated Amortization	(8,603)		(8,603)		(5,508)
Intangible Assets, net	63,347		63,347		$ 25,297
Amortization expense	1,198	$ 614	$ 3,095	$ 1,767
Trade names
Intangible Assets
Weighted Average Amortization Period			8 years 5 months 23 days		5 years
Gross Value	6,369		$ 6,369		$ 1,940
Accumulated Amortization	(1,102)		(1,102)		(791)
Intangible Assets, net	5,267		$ 5,267		$ 1,149
Client relationships
Intangible Assets
Weighted Average Amortization Period			8 years 6 months 22 days		10 years 7 days
Gross Value	34,263		$ 34,263		$ 14,684
Accumulated Amortization	(4,528)		(4,528)		(3,289)
Intangible Assets, net	29,735		$ 29,735		$ 11,395
Non-competition agreement intangible asset
Intangible Assets
Weighted Average Amortization Period			4 years 11 months 12 days		4 years 7 months 21 days
Gross Value	5,149		$ 5,149		$ 652
Accumulated Amortization	(465)		(465)		(326)
Intangible Assets, net	4,684		$ 4,684		$ 326
Developed technology
Intangible Assets
Weighted Average Amortization Period			7 years 10 months 13 days		7 years 9 months 4 days
Gross Value	26,140		$ 26,140		$ 13,500
Accumulated Amortization	(2,504)		(2,504)		(1,101)
Intangible Assets, net	23,636		$ 23,636		$ 12,399
Domain name
Intangible Assets
Weighted Average Amortization Period			10 years		10 years
Gross Value	29		$ 29		$ 29
Accumulated Amortization	(4)		(4)		(1)
Intangible Assets, net	$ 25		$ 25		$ 28

Goodwill and Intangible Asset48

Goodwill and Intangible Assets - Amortization (Details) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Estimated amortization expense
2017 (Remainder of year)	$ 2,398
2,018	9,557
2,019	9,115
2,020	8,776
2,021	8,763
Thereafter	24,738
Total estimated amortization expense	$ 63,347	$ 25,297

Accrued Expenses and Other Li49

Accrued Expenses and Other Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Accrued Liabilities and Other Liabilities
Employee related expenses	$ 4,634	$ 1,174
Deferred revenue	1,526	851
Contract labor	733
Interest	115	16
Deferred rent	150	13
Professional fees	169
Income taxes payable	281	27
Other expenses	493	78
Total accrued expenses and other liabilities	$ 8,101	$ 2,159

Notes Payable Related to Acqu50

Notes Payable Related to Acquisition (Details) - Medliance - Subordinated convertible promissory notes - USD ($) $ in Thousands	1 Months Ended	3 Months Ended	9 Months Ended
	Dec. 31, 2014	Sep. 30, 2016	Sep. 30, 2016
Notes Payable Related to Acquisition
Aggregate borrowings	$ 16,385
Interest rate (as a percent)	8.00%
Interest expense		$ 0	$ 706
Fair value of promissory notes	$ 14,347
Term of debt	18 months
Amortization of discount to interest expense		$ 0	$ 755

Lines of Credit and Long-Term51

Lines of Credit and Long-Term Debt - Lines of Credit (Details) - 2015 Revolving Line $ in Thousands	Jul. 01, 2016USD ($)	Sep. 30, 2017USD ($)	Dec. 31, 2016USD ($)	Sep. 30, 2016USD ($)	Sep. 30, 2017USD ($)item	Sep. 30, 2016USD ($)	Sep. 06, 2017USD ($)	Sep. 30, 2015USD ($)
Lines of Credit
Maximum borrowing capacity	$ 25,000						$ 40,000
Number of months of monthly recurring revenue through March 31, 2017	4 months
Number of months of monthly recurring revenue thereafter	3 months
Minimum unrestricted cash and unused availability balance required	$ 3,000
Minimum EBITDA			$ 2,500
Minimum monthly recurring revenue retention rate (as a percent)	90.00%
Sublimit of loan							1,000
Additional borrowing capacity							$ 10,000
Unrestricted cash and unused availability balance		$ 3,000			$ 3,000
Number of trailing months | item					12
Trailing period					12 months
Letter of credit outstanding		500	$ 500		$ 500			$ 500
Aggregate borrowings outstanding		35,000			35,000
Amounts available for borrowings		$ 4,500			$ 4,500
Interest rate (as a percent)		4.31%		4.56%	4.31%	4.56%
Interest expense		$ 100		$ 169	$ 100	$ 449
Deferred financing costs		413			413
Amortization of deferred financing costs to interest expense		$ 16		$ 9	$ 40	$ 36
Prime Rate
Lines of Credit
Spread on variable rate (as a percent)	0.50%
Floor rate (as a percent)	3.50%				3.50%
Minimum
Lines of Credit
Minimum EBITDA (as a percent)					75.00%
Minimum | Prime Rate
Lines of Credit
Spread on variable rate (as a percent)					(0.25%)
Maximum
Lines of Credit
Leverage ratio					2.50%
Maximum capital expenditure					$ 5,000
Maximum | Prime Rate
Lines of Credit
Spread on variable rate (as a percent)					0.25%

Lines of Credit and Long-Term52

Lines of Credit and Long-Term Debt - Capital Lease Obligations (Details) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Capital Lease Obligations
Capital leases	$ 1,946	$ 1,746
Less current portion	(927)	(674)
Total capital leases, less current portion, net	$ 1,019	$ 1,072

Lines of Credit and Long-Term53

Lines of Credit and Long-Term Debt - Capital Leases (Details) - Capital Lease Obligation - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016
Capital Lease Obligations
Interest expense, capital lease	$ 49	$ 56	$ 158	$ 148
Net book value of assets under capital leases	$ 2,213		$ 2,213		$ 2,364
Minimum
Capital Lease Obligations
Lease interest rates (as a percent)	6.00%		6.00%
Maximum
Capital Lease Obligations
Lease interest rates (as a percent)	19.00%		19.00%

Lines of Credit and Long-Term54

Lines of Credit and Long-Term Debt - Long-Term Debt Maturities (Details) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Long-Term Debt Maturities
Remainder of 2017	$ 293
2,018	1,065
2,019	725
2,020	116
2,021	5
Total	2,204
Less amount representing interest	(258)
Present value of payments	1,946
Less current portion	(927)	$ (674)
Total long-term debt, net of current portion	$ 1,019	$ 1,072

Lines of Credit and Long-Term55

Lines of Credit and Long-Term Debt - Other Financing (Details) - AmerisourceBergen Drug Corporation - USD ($) $ in Thousands	1 Months Ended
	May 31, 2016	Sep. 30, 2017	Dec. 31, 2016
Other Financing
Monthly minimum purchase obligation	$ 1,750
Purchase obligation, period	3 years
Amount due as a result of prescription drug purchases		$ 3,839	$ 3,327

Income Taxes - Expense (Details

Income Taxes - Expense (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Income Taxes
Income tax (benefit) expense	$ (8,105)	$ (164)	$ (7,845)	$ 11
Release of deferred tax asset valuation allowance			6,590
Income tax benefit, Tax windfall			2,830
Tax expense based on estimated annual effective tax rate expected			$ 1,463
Effective tax rate (as a percent)				(5.30%)
SinfoniaRx
Income Taxes
Net deferred tax liability recognized	$ 8,897

Other Long-term Liabilities (De

Other Long-term Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Other Long-term Liabilities.
Other Long-term Liabilities
Long-term portion of deferred rent	$ 2,637	$ 2,205

Stockholders' Equity - Capitali

Stockholders' Equity - Capitalization and IPO (Details) - USD ($) $ / shares in Units, $ in Thousands	Oct. 04, 2016	Sep. 30, 2017	Dec. 31, 2016
Capitalization and Initial Public Offering
Common stock authorized shares	100,000,000	100,000,000	100,000,000
Shares of common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001	$ 0.0001
Shares of undesignated preferred stock, authorized	10,000,000	10,000,000	10,000,000
Shares of undesignated preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001	$ 0.0001
IPO
Capitalization and Initial Public Offering
Issuance of common stock upon public offering, net of issuance costs (in shares)	4,300,000
Issuance price (in dollars per share)	$ 12
Proceeds from issuance of common stock under initial public offering, net of underwriting costs	$ 55,186
Underwriting discounts and commissions	$ 4,154
Underwriter option
Capitalization and Initial Public Offering
Issuance of common stock upon public offering, net of issuance costs (in shares)	645,000
Common Stock
Capitalization and Initial Public Offering
Redesignation of Class A and Class B common stock upon initial public offering (in shares)	5,583,405
Conversion of redeemable convertible preferred stock upon initial public offering (in shares)	5,089,436

Stockholders' Equity - Common S

Stockholders' Equity - Common Stock Warrants (Details) - $ / shares	Oct. 04, 2016	Sep. 30, 2017	Sep. 30, 2016
Common stock warrants
Warrants
Warrants exercised (in shares)		32,216	232,787
Exercise Price (in dollars per share)		$ 1.55
Number of warrants outstanding		0
Common Stock
Warrants
Shares issued upon exercise of warrants (in shares)	202,061	28,431	210,817

Stockholders' Equity - Common60

Stockholders' Equity - Common Stock Repurchase (Details) - USD ($) $ / shares in Units, $ in Thousands	9 Months Ended
	Sep. 30, 2017	Apr. 25, 2017
Common Stock Repurchase
Average price per share (in dollars per share)	$ 13.05
Shares repurchased (in dollars)	$ 959
Held in Treasury
Common Stock Repurchase
Shares repurchased (in shares)	73,466
Shares repurchased (in dollars)	$ 959
Common Stock
Common Stock Repurchase
Number of shares authorized to be repurchased		$ 5,000
Common stock available for repurchase	$ 4,041

Stock-Based Compensation - Plan

Stock-Based Compensation - Plans (Details) - shares	Sep. 28, 2016	Sep. 30, 2017	Sep. 30, 2017
Stock options
Stock-Based Compensation
Expiration term		10 years
Vesting period		4 years
Stock options | Vesting, Tranche 1
Stock-Based Compensation
Vesting period		1 year
Vesting (as a percent)		25.00%
Stock options | Vesting, Tranche 2
Stock-Based Compensation
Period of monthly vesting		36 months
Monthly vesting (as a percent)		2.08%
Stock options | Employee owning more than 10% of voting power
Stock-Based Compensation
Expiration term		5 years
Expiration term after termination		90 days
Expiration term after death or termination due to disability		1 year
Stock options | Minimum | Employee owning more than 10% of voting power
Stock-Based Compensation
Ownership (as a percent)		10.00%	10.00%
Option price as percentage of fair market value of common stock on the date of grant		110.00%
2014 Plan | Restricted stock
Stock-Based Compensation
Awards, other than options, granted (in shares)			0
2014 Plan | Stock options
Stock-Based Compensation
Options granted (in shares)			0
2016 Plan
Stock-Based Compensation
Options granted (in shares)		1,044,556
Threshold limit to issue or transfer authorized shares (in shares)	800,000
Automatic increase on share reserve (as a percent)	5.00%
Additional shares authorized		831,423
Available for future grant (in shares)		459,368	459,368

Stock-Based Compensation - Empl

Stock-Based Compensation - Employee Restricted Common Stock (Details) - USD ($) $ / shares in Units, $ in Thousands	Aug. 03, 2017	Sep. 28, 2016	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Stock-Based Compensation
Stock-based compensation expense (in dollars)			$ 939	$ 223	$ 7,776	$ 481
Restricted stock | Employees | Award Date of September 28, 2016
Stock-Based Compensation
Awards, other than options, granted (in shares)		700,386
Share price (in dollars per share)		$ 12
Stock-based compensation expense (in dollars)			0	$ 102	5,159	$ 102
Unrecognized compensation expense (in dollars)			0		0
Restricted stock | Employees | Award Date August 3, 2017
Stock-Based Compensation
Awards, other than options, granted (in shares)	20,000
Share price (in dollars per share)	$ 14.56
Stock-based compensation expense (in dollars)			12		12
Unrecognized compensation expense (in dollars)			$ 279		$ 279
Annual vesting (as a percent)	25.00%
Vesting period	4 years

Stock-Based Compensation - Non-

Stock-Based Compensation - Non-Employee Director Restricted Stock (Details) - USD ($) $ / shares in Units, $ in Thousands	Sep. 28, 2017	Jun. 16, 2017	Mar. 08, 2017	Sep. 28, 2016	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Stock-Based Compensation
Stock-based compensation expense (in dollars)					$ 939	$ 223	$ 7,776	$ 481
Restricted stock | Non-employee directors
Stock-Based Compensation
Stock-based compensation expense (in dollars)					56	$ 1	165	$ 1
Unrecognized compensation expense (in dollars)					$ 276		$ 276
Restricted stock | Non-employee directors | Award Date of September 28, 2016
Stock-Based Compensation
Awards, other than options, granted (in shares)				22,260
Share price (in dollars per share)				$ 12
Restricted stock | Non-employee directors | Award Date of March 8, 2017
Stock-Based Compensation
Awards, other than options, granted (in shares)			5,212
Annual vesting (as a percent)			33.33%
Vesting period			3 years
Share price (in dollars per share)			$ 13.68
Restricted Stock, Annual grant | Non-employee directors | Award Date of September 28, 2016
Stock-Based Compensation
Vested (in shares)		7,420
Restricted Stock, Annual grant | Non-employee directors | Award Date June 16, 2017
Stock-Based Compensation
Awards, other than options, granted (in shares)		10,384
Share price (in dollars per share)		$ 13.54
Restricted Stock, Annual grant | Maximum | Non-employee directors | Award Date of September 28, 2016
Stock-Based Compensation
Vesting period				1 year
Restricted Stock, Annual grant | Maximum | Non-employee directors | Award Date June 16, 2017
Stock-Based Compensation
Vesting period		1 year
Restricted Stock, Initial grant | Non-employee directors | Award Date of September 28, 2016
Stock-Based Compensation
Annual vesting (as a percent)				33.33%
Vesting period				3 years
Vested (in shares)	4,944

Stock-Based Compensation - Opti

Stock-Based Compensation - Options Valuation (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Stock-Based Compensation
Stock-based compensation expense (in dollars)	$ 939	$ 223	$ 7,776	$ 481
Stock options
Stock-Based Compensation
Stock-based compensation expense (in dollars)	$ 871	$ 120	$ 2,440	$ 378
Employee stock options
Valuation assumptions:
Expected volatility (as a percent)			61.00%	59.00%
Expected life			6 years 11 days	6 years 29 days
Risk-free interest rate (as a percent)			2.21%	1.49%
Weighted average grant-date fair value (in dollars per share)			$ 8.13	$ 7.29

Stock-Based Compensation - Op65

Stock-Based Compensation - Options Activity (Details) $ / shares in Units, $ in Thousands	9 Months Ended
	Sep. 30, 2017USD ($)$ / sharesshares	Sep. 30, 2016USD ($)shares
Additional disclosures
Intrinsic value of options exercised (in dollars) | $	$ 11,665	$ 832
Proceeds from stock options exercised (in dollars) | $	$ 194	$ 0
Shares delivered as payment for exercise	362,440	7,930
Stock options exercised in cashless transaction	956,327	71,150
Gross cashless exercise value | $	$ 3,187	$ 104
2016 Plan
Number of shares
Outstanding at beginning of period (in shares)	3,059,690
Granted (in shares)	1,044,556
Exercised (in shares)	(1,054,764)
Forfeited (in shares)	(49,629)
Outstanding at end of the period (in shares)	2,999,853
Options vested and expected to vest at end of the period (in shares)	2,999,853
Exercisable at end of period (in shares)	1,393,742
Weighted average exercise price
Outstanding at beginning of period (in dollars per share) | $ / shares	$ 5.14
Granted (in dollars per share) | $ / shares	14.43
Exercised (in dollars per share) | $ / shares	3.21
Forfeited (in dollars per share) | $ / shares	10.52
Outstanding at end of period (in dollars per share) | $ / shares	8.97
Options vested and expected to vest at end of period (in dollars per share) | $ / shares	8.97
Exercisable at end of period (in dollars per share) | $ / shares	$ 3.37
Weighted average remaining contractual term
Outstanding	7 years 3 months 18 days
Options vested and expected to vest at of the period	7 years 3 months 18 days
Exercisable	5 years 3 months 18 days
Aggregate intrinsic value
Outstanding (in dollars) | $	$ 53,340
Options vested and expected to vest at end of period (in dollars) | $	53,340
Exercisable (in dollars) | $	32,572
Stock options | 2016 Plan
Additional disclosures
Total unrecognized compensation cost (in dollars) | $	$ 10,022
Weighted average period expected to be recognized	2 years 10 months 24 days
Non-employee options | 2016 Plan
Number of shares
Outstanding at end of the period (in shares)	150,212
Additional disclosures
Unvested options (in shares)	345

Stock-Based Compensation - Expe

Stock-Based Compensation - Expense (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Stock-based compensation expense
Stock-based compensation expense (in dollars)	$ 939	$ 223	$ 7,776	$ 481
Cost of revenue - product
Stock-based compensation expense
Stock-based compensation expense (in dollars)	138	27	359	85
Cost of revenue - service
Stock-based compensation expense
Stock-based compensation expense (in dollars)	91	7	203	21
Research and development
Stock-based compensation expense
Stock-based compensation expense (in dollars)	195	9	515	30
Sales and marketing
Stock-based compensation expense
Stock-based compensation expense (in dollars)	158	21	440	65
General and administrative
Stock-based compensation expense
Stock-based compensation expense (in dollars)	$ 357	$ 159	$ 6,259	$ 280

Fair Value Measurements - Liabi

Fair Value Measurements - Liabilities (Details) - Recurring - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Fair Value Measurements
Acquisition-related contingent consideration - short-term	$ 15,224	$ 1,493
Acquisition-related contingent consideration - long-term	13,652	1,515
Liabilities	28,876	3,008
Level 3
Fair Value Measurements
Acquisition-related contingent consideration - short-term	15,224	1,493
Acquisition-related contingent consideration - long-term	13,652	1,515
Liabilities	$ 28,876	$ 3,008

Fair Value Measurements - Conti

Fair Value Measurements - Contingent consideration Rollforward (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2017USD ($)
Acquisition related contingent consideration
Change in fair value using significant unobservable inputs (Level 3):
Balance at beginning of period	$ 3,008
Acquisition date fair value of SinfoniaRx contingent consideration	26,406
Fair value of cash consideration paid	(1,498)
Adjustments to fair value measurement	960
Balance at end of period	28,876
SinfoniaRx
Change in fair value
Fair value of contingent consideration	27,313
Medliance
Change in fair value
Fair value of contingent consideration	$ 1,563

Commitments and Contingencies -

Commitments and Contingencies - Letter of Credit (Details) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016	Sep. 30, 2015
2015 Revolving Line
Letter of Credit
Letter of credit outstanding	$ 500	$ 500	$ 500

Retirement Plan (Details)

Retirement Plan (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Retirement Plan
Contributions by employer	$ 194	$ 128	$ 478	$ 230

Employment Agreements (Details)

Employment Agreements (Details)	Apr. 25, 2017
Employment agreements, Named executive officers, April 25, 2017
Employment Agreements and Incentive Arrangements
Term of agreement	3 years

Related-Party Transactions (Det

Related-Party Transactions (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2016USD ($)
Tunstall Consulting
Related-Party Transactions
Cost incurred	$ 104